PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
18786552-1	2009	Amongst the family members of Cys-loop LGICs, the atypical ability of the 5-HT3A subunit to form functional homomeric receptors allowed a direct investigation of the role of the C-terminus.	Cysteine	30-33	5-hydroxytryptamine receptor 3A	Homo sapiens	74-80
18474595-3	2008	Mutation of cytoplasmic arginine residues 432, 436, and 440 to glutamine, aspartate, and alanine (the aligned residues of the human 5-HT3B subunit (yielding 5-HT3A(QDA)) increased PCa/PCs from 1.4 to 3.7.	N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine	164-167	5-hydroxytryptamine receptor 3A	Homo sapiens	157-163
18622264-0	2008	Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients.	Risperidone	81-92	5-hydroxytryptamine receptor 3A	Homo sapiens	42-47
18622264-4	2008	METHODS: The study recruited 107 drug-naive Chinese schizophrenia patients who were given 8 weeks of risperidone monotherapy and it explored three of four single nucleotide polymorphisms spanning HTR3A for possible association with therapeutic improvement, using the Positive and Negative Symptom Scale.	Risperidone	101-112	5-hydroxytryptamine receptor 3A	Homo sapiens	196-201
18622264-9	2008	CONCLUSION: The results of this study are the first to suggest that the polymorphism of HTR3A may be a useful predictor of therapeutic response to risperidone treatment in Chinese schizophrenic patients, although these conclusions should be treated with caution because of the intricacy of the variety of the therapeutic effects to risperidone.	Risperidone	147-158	5-hydroxytryptamine receptor 3A	Homo sapiens	88-93
19086332-2	2008	Factors predicting treatment responsiveness are not known, although we have demonstrated that symptom improvement with the 5-HT3R antagonist alosetron is correlated with reduced amygdala activity.	alosetron	141-150	5-hydroxytryptamine receptor 3A	Homo sapiens	123-129
19086332-8	2008	CONCLUSIONS: Irritable bowel disease symptom improvement with 5-HT3R antagonist alosetron is related to pre-treatment reactivity of the left OFC, which may be partially captured by subjective measures of interpersonal sensitivity.	alosetron	80-89	5-hydroxytryptamine receptor 3A	Homo sapiens	62-68
18622264-9	2008	CONCLUSION: The results of this study are the first to suggest that the polymorphism of HTR3A may be a useful predictor of therapeutic response to risperidone treatment in Chinese schizophrenic patients, although these conclusions should be treated with caution because of the intricacy of the variety of the therapeutic effects to risperidone.	Risperidone	332-343	5-hydroxytryptamine receptor 3A	Homo sapiens	88-93
18670328-5	2008	Among the currently available 5-hydroxytryptamine receptor 3 antagonists (5-HT3), ondansetron is being most widely used with unsatisfactory results regarding opioid-based IV PCA related PONV.	Ondansetron	82-93	5-hydroxytryptamine receptor 3A	Homo sapiens	30-60
18474595-2	2008	We examined the influence on Ca2+ permeation of amino acids located at intra- and extracellular ends of the conduction pathway of the human 5-hydroxytryptamine type 3A (5-HT3A) receptor.	Serotonin	140-159	5-hydroxytryptamine receptor 3A	Homo sapiens	169-175
18474595-6	2008	A conserved aspartate, located toward the extracellular end of the conduction pathway and known to influence ionic selectivity, contributed to the inhibitory effect of Ca2+ on macroscopic currents mediated by 5-HT3A receptors.	Aspartic Acid	12-21	5-hydroxytryptamine receptor 3A	Homo sapiens	209-215
18635474-0	2008	The effects of fentanyl-like opioids and hydromorphone on human 5-HT3A receptors.	Hydromorphone	41-54	5-hydroxytryptamine receptor 3A	Homo sapiens	64-70
17161536-1	2007	Despite its beneficial effect in IBS patients, the mechanism of action of the 5-HT3 receptor (5-HT3R) antagonist alosetron is still incompletely understood.	alosetron	113-122	5-hydroxytryptamine receptor 3A	Homo sapiens	78-92
18379051-6	2008	In oocytes expressing glycine or 5-HT3A receptors, quercetin- or its glycosides-induced inhibitions on glycine- (IGly) and 5-HT-induced current (I5-HT) were dose-dependent and reversible.	Glycine	103-110	5-hydroxytryptamine receptor 3A	Homo sapiens	33-39
18379051-10	2008	These results also indicate that quercetin glycosides might regulate the human glycine alpha1 and mouse 5-HT3A receptors with differential manners.	Rutin	33-53	5-hydroxytryptamine receptor 3A	Homo sapiens	104-110
18311193-4	2008	KEY RESULTS: 5-HT(3A) receptor responses were inhibited by mefloquine, quinine and chloroquine with IC(50) values of 0.66, 1.06 and 24.3 microM.	Mefloquine	59-69	5-hydroxytryptamine receptor 3A	Homo sapiens	13-20
18311193-4	2008	KEY RESULTS: 5-HT(3A) receptor responses were inhibited by mefloquine, quinine and chloroquine with IC(50) values of 0.66, 1.06 and 24.3 microM.	Chloroquine	83-94	5-hydroxytryptamine receptor 3A	Homo sapiens	13-20
18311193-11	2008	CONCLUSIONS AND IMPLICATIONS: The effects of mefloquine, quinine and chloroquine are distinct at GABA(A) and GABA(C) receptors, whereas their effects on 5-HT(3AB) receptors are broadly similar to those at 5-HT(3A) receptors.	Mefloquine	45-55	5-hydroxytryptamine receptor 3A	Homo sapiens	153-160
18311193-11	2008	CONCLUSIONS AND IMPLICATIONS: The effects of mefloquine, quinine and chloroquine are distinct at GABA(A) and GABA(C) receptors, whereas their effects on 5-HT(3AB) receptors are broadly similar to those at 5-HT(3A) receptors.	Chloroquine	69-80	5-hydroxytryptamine receptor 3A	Homo sapiens	153-160
18292429-12	2008	CONCLUSIONS: At least two separate inhibitory actions on 5-HT3A receptors could be identified for propofol, whereas the enhancing action seen for the two related smaller phenol derivatives could no longer be detected.	Propofol	98-106	5-hydroxytryptamine receptor 3A	Homo sapiens	57-63
17993512-0	2008	Anandamide inhibition of 5-HT3A receptors varies with receptor density and desensitization.	anandamide	0-10	5-hydroxytryptamine receptor 3A	Homo sapiens	25-31
18045909-0	2007	Differential effects of serotonin and dopamine on human 5-HT3A receptor kinetics: interpretation within an allosteric kinetic model.	Serotonin	24-33	5-hydroxytryptamine receptor 3A	Homo sapiens	56-62
18045909-0	2007	Differential effects of serotonin and dopamine on human 5-HT3A receptor kinetics: interpretation within an allosteric kinetic model.	Dopamine	38-46	5-hydroxytryptamine receptor 3A	Homo sapiens	56-62
18045909-3	2007	In this study, we report the results of electrophysiological studies using rapid solution exchange designed to characterize and compare the actions of the high-efficacy agonist serotonin and the low-efficacy agonist dopamine on human 5-HT3A receptors expressed in human embryonic kidney HEK293 cells.	Serotonin	177-186	5-hydroxytryptamine receptor 3A	Homo sapiens	234-240
18045909-3	2007	In this study, we report the results of electrophysiological studies using rapid solution exchange designed to characterize and compare the actions of the high-efficacy agonist serotonin and the low-efficacy agonist dopamine on human 5-HT3A receptors expressed in human embryonic kidney HEK293 cells.	Dopamine	216-224	5-hydroxytryptamine receptor 3A	Homo sapiens	234-240
17669396-0	2007	Inhibition of human 5-HT(3A) and 5-HT(3AB) receptors by etomidate, propofol and pentobarbital.	Etomidate	56-65	5-hydroxytryptamine receptor 3A	Homo sapiens	20-27
17669396-0	2007	Inhibition of human 5-HT(3A) and 5-HT(3AB) receptors by etomidate, propofol and pentobarbital.	Propofol	67-75	5-hydroxytryptamine receptor 3A	Homo sapiens	20-27
17669396-0	2007	Inhibition of human 5-HT(3A) and 5-HT(3AB) receptors by etomidate, propofol and pentobarbital.	Pentobarbital	80-93	5-hydroxytryptamine receptor 3A	Homo sapiens	20-27
17669396-2	2007	Using oocyte electrophysiology, the effects of etomidate, propofol, and pentobarbital on human 5-HT(3A) and 5-HT(3AB) receptors were studied and compared.	Pentobarbital	72-85	5-hydroxytryptamine receptor 3A	Homo sapiens	95-102
17669396-4	2007	Because the half-maximal inhibitory concentrations for etomidate, propofol and pentobarbital in 5-HT(3A) and 5-HT(3AB) receptors were all above their respective anaesthetic concentrations, the results of our study suggest that neither 5-HT(3) receptor subtype contributes to the anaesthetic actions of etomidate, propofol or pentobarbital.	Etomidate	55-64	5-hydroxytryptamine receptor 3A	Homo sapiens	96-103
17669396-4	2007	Because the half-maximal inhibitory concentrations for etomidate, propofol and pentobarbital in 5-HT(3A) and 5-HT(3AB) receptors were all above their respective anaesthetic concentrations, the results of our study suggest that neither 5-HT(3) receptor subtype contributes to the anaesthetic actions of etomidate, propofol or pentobarbital.	Propofol	66-74	5-hydroxytryptamine receptor 3A	Homo sapiens	96-103
17669396-4	2007	Because the half-maximal inhibitory concentrations for etomidate, propofol and pentobarbital in 5-HT(3A) and 5-HT(3AB) receptors were all above their respective anaesthetic concentrations, the results of our study suggest that neither 5-HT(3) receptor subtype contributes to the anaesthetic actions of etomidate, propofol or pentobarbital.	Pentobarbital	79-92	5-hydroxytryptamine receptor 3A	Homo sapiens	96-103
17637025-0	2007	1-Oxo-5-hydroxytryptamine: a surprisingly potent agonist of the 5-HT3 (serotonin) receptor.	1-oxo-5-hydroxytryptamine	0-25	5-hydroxytryptamine receptor 3A	Homo sapiens	64-90
18379051-3	2008	In the previous studies, we demonstrated that quercetin inhibits both glycine and 5-hydroxytryptamine type 3, (5-HT3A) receptor channel activities expressed in Xenopus oocytes.	Quercetin	46-55	5-hydroxytryptamine receptor 3A	Homo sapiens	111-117
18379051-4	2008	However, the effects of quercetin glycosides on glycine and 5-HT3A receptor channel activities are not well known.	Rutin	24-44	5-hydroxytryptamine receptor 3A	Homo sapiens	60-66
18379051-6	2008	In oocytes expressing glycine or 5-HT3A receptors, quercetin- or its glycosides-induced inhibitions on glycine- (IGly) and 5-HT-induced current (I5-HT) were dose-dependent and reversible.	Quercetin	51-60	5-hydroxytryptamine receptor 3A	Homo sapiens	33-39
18379051-6	2008	In oocytes expressing glycine or 5-HT3A receptors, quercetin- or its glycosides-induced inhibitions on glycine- (IGly) and 5-HT-induced current (I5-HT) were dose-dependent and reversible.	Glycosides	69-79	5-hydroxytryptamine receptor 3A	Homo sapiens	33-39
18292429-0	2008	Molecular actions of propofol on human 5-HT3A receptors: enhancement as well as inhibition by closely related phenol derivatives.	Propofol	21-29	5-hydroxytryptamine receptor 3A	Homo sapiens	39-45
18292429-0	2008	Molecular actions of propofol on human 5-HT3A receptors: enhancement as well as inhibition by closely related phenol derivatives.	Phenol	110-116	5-hydroxytryptamine receptor 3A	Homo sapiens	39-45
18292429-3	2008	To investigate the molecular mechanisms responsible for these contrasting actions, we examined the kinetics of the action of propofol and its lesser hydrophobic derivatives 2-isopropylphenol and phenol on human 5-HT3A receptors.	Propofol	125-133	5-hydroxytryptamine receptor 3A	Homo sapiens	211-217
18292429-3	2008	To investigate the molecular mechanisms responsible for these contrasting actions, we examined the kinetics of the action of propofol and its lesser hydrophobic derivatives 2-isopropylphenol and phenol on human 5-HT3A receptors.	2-isopropylphenol	173-190	5-hydroxytryptamine receptor 3A	Homo sapiens	211-217
18292429-6	2008	RESULTS: When applied in equilibrium (60 s before and during the 5-HT pulse), propofol inhibited human 5-HT3A receptors (IC50 = 18 +/- 1.0 microM).	Propofol	78-86	5-hydroxytryptamine receptor 3A	Homo sapiens	103-109
18292429-7	2008	In equilibrium, the less hydrophobic 2-isopropylphenol was surprisingly a similarly potent inhibitor of human 5-HT3A receptors (IC50 = 17 +/- 3.2 microM), whereas phenol was considerably less potent (IC50 = 1.6 +/- 0.2 mM).	2-isopropylphenol	37-54	5-hydroxytryptamine receptor 3A	Homo sapiens	110-116
18292429-7	2008	In equilibrium, the less hydrophobic 2-isopropylphenol was surprisingly a similarly potent inhibitor of human 5-HT3A receptors (IC50 = 17 +/- 3.2 microM), whereas phenol was considerably less potent (IC50 = 1.6 +/- 0.2 mM).	Phenol	48-54	5-hydroxytryptamine receptor 3A	Homo sapiens	110-116
18082160-2	2008	Here we show that 5-fluorotryptamine (5-FT) is a partial agonist at both 5-HT3A and 5-HT3AB receptors with an Rmax (Imax/Imax 5-HT) of 0.64 and 0.45 respectively.	5-fluorotryptamine	18-36	5-hydroxytryptamine receptor 3A	Homo sapiens	73-85
18082160-2	2008	Here we show that 5-fluorotryptamine (5-FT) is a partial agonist at both 5-HT3A and 5-HT3AB receptors with an Rmax (Imax/Imax 5-HT) of 0.64 and 0.45 respectively.	5-fluorotryptamine	38-42	5-hydroxytryptamine receptor 3A	Homo sapiens	73-85
17656445-3	2007	The aims of this study were to evaluate the effects of the 5-HT3 antagonist granisetron on the BP, heart rate (HR), and antropyloroduodenal (APD) motility responses to intraduodenal glucose in healthy older subjects.	Glucose	182-189	5-hydroxytryptamine receptor 3A	Homo sapiens	59-64
17161536-1	2007	Despite its beneficial effect in IBS patients, the mechanism of action of the 5-HT3 receptor (5-HT3R) antagonist alosetron is still incompletely understood.	alosetron	113-122	5-hydroxytryptamine receptor 3A	Homo sapiens	94-100
17360702-7	2007	Potentiation by smaller alcohols was consistently significantly greater in 5-HT(3A) than in 5-HT(3AB) receptors, whereas inhibition by larger alcohols was not.	Alcohols	24-32	5-hydroxytryptamine receptor 3A	Homo sapiens	75-82
16534507-1	2006	We investigated the effect of 5-hydroxytryptamine 3A and 3B receptor (HTR3A and HTR3B) gene polymorphisms on nausea induced by paroxetine in Japanese psychiatric patients.	Paroxetine	127-137	5-hydroxytryptamine receptor 3A	Homo sapiens	70-75
17562330-4	2007	Ondansetron, a 5-HT-3 serotonin receptor antagonist augmented significantly ADCC.	Ondansetron	0-11	5-hydroxytryptamine receptor 3A	Homo sapiens	15-40
16873768-6	2007	Further experiments with isotype-selective receptor agonists allowed us to demonstrate that 5-HT induced calcium transients via activation of 5-HTR1, 5-HTR2, and 5-HTR3 in A549 and BEAS-2B cells.	Calcium	105-112	5-hydroxytryptamine receptor 3A	Homo sapiens	164-168
17692006-9	2007	Of all GlyR potentiating substances identified to date, we conclude that 5HT(3)R antagonists such as tropisetron offer the most promise as therapeutic lead compounds.	Tropisetron	101-112	5-hydroxytryptamine receptor 3A	Homo sapiens	73-80
16931691-0	2006	The effects of morphine on human 5-HT3A receptors.	Morphine	15-23	5-hydroxytryptamine receptor 3A	Homo sapiens	33-39
16427041-5	2006	A similar low potent inhibition of human 5-HT(3A) receptors was found for (+) and (-) O-demethyl-tramadol (IC50=158 and 63 microM, respectively).	O-demethyltramadol	86-105	5-hydroxytryptamine receptor 3A	Homo sapiens	41-48
16551836-0	2006	N-terminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine.	benzylidene	122-133	5-hydroxytryptamine receptor 3A	Homo sapiens	38-59
16551836-0	2006	N-terminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine.	anabaseine	145-155	5-hydroxytryptamine receptor 3A	Homo sapiens	38-59
16551836-1	2006	The present study tested the hypothesis that mouse and human 5-hydroxytryptamine3A (5-HT3A) receptors may be differentially modulated by benzylidene analogs of anabaseine (BA) and that these analogs may be useful in assessing residues involved in receptor gating.	benzylidene	137-148	5-hydroxytryptamine receptor 3A	Homo sapiens	61-82
16551836-1	2006	The present study tested the hypothesis that mouse and human 5-hydroxytryptamine3A (5-HT3A) receptors may be differentially modulated by benzylidene analogs of anabaseine (BA) and that these analogs may be useful in assessing residues involved in receptor gating.	anabaseine	160-170	5-hydroxytryptamine receptor 3A	Homo sapiens	61-82
16551836-1	2006	The present study tested the hypothesis that mouse and human 5-hydroxytryptamine3A (5-HT3A) receptors may be differentially modulated by benzylidene analogs of anabaseine (BA) and that these analogs may be useful in assessing residues involved in receptor gating.	Barium	172-174	5-hydroxytryptamine receptor 3A	Homo sapiens	61-82
16551836-5	2006	BA compounds antagonized 1.5 microM 5-HT-mediated (EC50) responses in the HWT 5-HT3A receptor with a rank order of potency (IC50 in muM) of 2-OHMBA (1.5 +/- 0.1) > DMXBA (3.1 +/- 0.2) > 4-OHMBA (7.4 +/- 0.5) > 2,4-DiOHBA (12.8 +/- 0.7).	Barium	0-2	5-hydroxytryptamine receptor 3A	Homo sapiens	78-84
16551836-5	2006	BA compounds antagonized 1.5 microM 5-HT-mediated (EC50) responses in the HWT 5-HT3A receptor with a rank order of potency (IC50 in muM) of 2-OHMBA (1.5 +/- 0.1) > DMXBA (3.1 +/- 0.2) > 4-OHMBA (7.4 +/- 0.5) > 2,4-DiOHBA (12.8 +/- 0.7).	2-ohmba	140-147	5-hydroxytryptamine receptor 3A	Homo sapiens	78-84
16551836-5	2006	BA compounds antagonized 1.5 microM 5-HT-mediated (EC50) responses in the HWT 5-HT3A receptor with a rank order of potency (IC50 in muM) of 2-OHMBA (1.5 +/- 0.1) > DMXBA (3.1 +/- 0.2) > 4-OHMBA (7.4 +/- 0.5) > 2,4-DiOHBA (12.8 +/- 0.7).	3-(2,4-dimethoxybenzylidene)anabaseine	167-172	5-hydroxytryptamine receptor 3A	Homo sapiens	78-84
16551836-5	2006	BA compounds antagonized 1.5 microM 5-HT-mediated (EC50) responses in the HWT 5-HT3A receptor with a rank order of potency (IC50 in muM) of 2-OHMBA (1.5 +/- 0.1) > DMXBA (3.1 +/- 0.2) > 4-OHMBA (7.4 +/- 0.5) > 2,4-DiOHBA (12.8 +/- 0.7).	4-ohmba	192-199	5-hydroxytryptamine receptor 3A	Homo sapiens	78-84
16551836-5	2006	BA compounds antagonized 1.5 microM 5-HT-mediated (EC50) responses in the HWT 5-HT3A receptor with a rank order of potency (IC50 in muM) of 2-OHMBA (1.5 +/- 0.1) > DMXBA (3.1 +/- 0.2) > 4-OHMBA (7.4 +/- 0.5) > 2,4-DiOHBA (12.8 +/- 0.7).	2,4-diohba	219-229	5-hydroxytryptamine receptor 3A	Homo sapiens	78-84
16551836-8	2006	Thus, amino acids present in the distal one-third of the N terminus of mouse and human 5-HT3A receptors are necessary and sufficient to confer partial agonist or antagonist properties of 2-OHMBA.	2-ohmba	187-194	5-hydroxytryptamine receptor 3A	Homo sapiens	87-93
16874005-6	2006	The 178C/C genotype of the HTR3A was associated with an antidepressant response (p = 0.022-0.042), and more significantly in paroxetine-treated patients (p = 0.002-0.042).	Paroxetine	125-135	5-hydroxytryptamine receptor 3A	Homo sapiens	27-32
15920198-2	2005	Studies have shown that modulation of 5-HT3A receptor currents by n-alcohols depends on molecular volume, suggesting that steric interactions between n-alcohols and their binding sites define their action on this receptor.	n-alcohols	66-76	5-hydroxytryptamine receptor 3A	Homo sapiens	38-44
16221844-9	2005	Disulfide bonds formed in 5-HT3A/K81C/A304C and 5-HT3A/K81C/I305C when coexpressed with 5-HT3B.	Disulfides	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	26-32
16221844-9	2005	Disulfide bonds formed in 5-HT3A/K81C/A304C and 5-HT3A/K81C/I305C when coexpressed with 5-HT3B.	Disulfides	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	48-54
16314763-0	2005	Serotonin receptor genes HTR3A and HTR3B are not involved in Gilles de la Tourette syndrome.	Serotonin	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	25-30
15914697-1	2005	The serotonin type 3 receptor (5-HT(3)R) is a member of the cys-loop ligand-gated ion channel (LGIC) superfamily.	Cysteine	60-63	5-hydroxytryptamine receptor 3A	Homo sapiens	31-39
15814570-7	2005	Mutation of the 7" leucine to threonine in 5-HT3A receptors increased PTX sensitivity roughly 10-fold, comparable with that observed in GABA(A) receptors, and also conferred distinct gating kinetics.	Picrotoxin	70-73	5-hydroxytryptamine receptor 3A	Homo sapiens	43-49
15920198-2	2005	Studies have shown that modulation of 5-HT3A receptor currents by n-alcohols depends on molecular volume, suggesting that steric interactions between n-alcohols and their binding sites define their action on this receptor.	n-alcohols	150-160	5-hydroxytryptamine receptor 3A	Homo sapiens	38-44
15920198-9	2005	However, only agents smaller than 0.120 nm3 shifted the 5-HT3A receptor"s serotonin concentration-response curve to the left, whereas larger anesthetics shifted them to the right.	Serotonin	74-83	5-hydroxytryptamine receptor 3A	Homo sapiens	56-62
15920198-10	2005	Modulation of human 5-HT3A-mediated currents by volatile anesthetics exhibits a dependence on molecular volume consistent with the n-alcohols, suggesting that both classes of agents may enhance 5-HT3A receptor function via the same mechanism.	n-alcohols	131-141	5-hydroxytryptamine receptor 3A	Homo sapiens	20-26
15830306-11	2005	Palonosetron is a new drug in the class of 5-HT (3) (serotonin) receptor antagonists.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	43-72
15554432-4	2004	Administration of the 5-HT3 serotonin receptor subtype antagonist, ondansetron, has been associated with substantial sustained clinical ameliorations of profound fatigue in at least some patients with chronic liver disease.	Ondansetron	67-78	5-hydroxytryptamine receptor 3A	Homo sapiens	22-46
15683818-4	2005	Palonoestron (a 5-HT3R antagonist) and aprepitant (an antagonist for the protachykinin 1 receptor) have been introduced for the prevention of emesis.	palonoestron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	16-22
15157181-9	2004	Replacement of three arginine residues (R432, R436 and R440) unique to the HA stretch of the 5-HT3A subunit with the aligned residues (Q395, D399 and A403) of the 5-HT3B subunit increased the single-channel conductance 28-fold.	Arginine	21-29	5-hydroxytryptamine receptor 3A	Homo sapiens	93-99
15318223-3	2004	Here we identify structural requirements for functionally coupling the two domains by combining acetylcholine (ACh)-binding protein, whose structure was determined at atomic resolution, with the pore domain from the serotonin type-3A (5-HT3A) receptor.	Acetylcholine	96-109	5-hydroxytryptamine receptor 3A	Homo sapiens	235-241
15318223-4	2004	Only when amino-acid sequences of three loops in ACh-binding protein are changed to their 5-HT3A counterparts does ACh bind with low affinity characteristic of activatable receptors, and trigger opening of the ion pore.	Acetylcholine	49-52	5-hydroxytryptamine receptor 3A	Homo sapiens	90-96
15515405-1	2004	There is evidence from both human and animal research that 5-hydroxytryptamine3 (5-HT3) receptor antagonists, particularly tropisetron, exert analgesic and antiinflammatory effects.	Tropisetron	123-134	5-hydroxytryptamine receptor 3A	Homo sapiens	81-86
15541891-6	2004	In both preparations, the 5-HT effect was shown to be mediated by 5HT3Rs, as it was mimicked by the selective 5HT3R agonist m-chlorophenyl biguanide and blocked by the selective 5HT3R antagonist 3-tropanylindole-3-carboxylate hydrochloride.	1-(3-chlorophenyl)biguanide	124-148	5-hydroxytryptamine receptor 3A	Homo sapiens	66-71
15541891-6	2004	In both preparations, the 5-HT effect was shown to be mediated by 5HT3Rs, as it was mimicked by the selective 5HT3R agonist m-chlorophenyl biguanide and blocked by the selective 5HT3R antagonist 3-tropanylindole-3-carboxylate hydrochloride.	1-(3-chlorophenyl)biguanide	124-148	5-hydroxytryptamine receptor 3A	Homo sapiens	110-115
15541891-6	2004	In both preparations, the 5-HT effect was shown to be mediated by 5HT3Rs, as it was mimicked by the selective 5HT3R agonist m-chlorophenyl biguanide and blocked by the selective 5HT3R antagonist 3-tropanylindole-3-carboxylate hydrochloride.	Tropisetron hydrochloride	195-239	5-hydroxytryptamine receptor 3A	Homo sapiens	66-71
15541891-7	2004	The 5HT3R-mediated increase in GABA release was blocked by 100 microM cadmium or by omitting Ca2+ in external solutions, indicating the Ca2+-dependence of the effect.	gamma-Aminobutyric Acid	31-35	5-hydroxytryptamine receptor 3A	Homo sapiens	4-9
15541891-7	2004	The 5HT3R-mediated increase in GABA release was blocked by 100 microM cadmium or by omitting Ca2+ in external solutions, indicating the Ca2+-dependence of the effect.	Cadmium	70-77	5-hydroxytryptamine receptor 3A	Homo sapiens	4-9
15102340-7	2004	CONCLUSIONS: The present results suggest that the HTR3A and DBH genes may participate in the regulation of dopamine and serotonin turnover rates in the central nervous system.	Dopamine	107-115	5-hydroxytryptamine receptor 3A	Homo sapiens	50-55
15102340-7	2004	CONCLUSIONS: The present results suggest that the HTR3A and DBH genes may participate in the regulation of dopamine and serotonin turnover rates in the central nervous system.	Serotonin	120-129	5-hydroxytryptamine receptor 3A	Homo sapiens	50-55
15055527-0	2004	Differential effect of ginsenoside metabolites on the 5-HT3A receptor-mediated ion current in Xenopus oocytes.	Ginsenosides	23-34	5-hydroxytryptamine receptor 3A	Homo sapiens	54-60
15055527-5	2004	In previous work we demonstrated that the ginsenoside Rg2 regulates human 5-hydroxytryptamine3A (5-HT3A) receptor channel activity [Choi et al.	Ginsenosides	42-53	5-hydroxytryptamine receptor 3A	Homo sapiens	97-103
15055527-13	2004	These results indicate that M4, a metabolite of PT ginsenosides, acts primarily on 5-HT3A receptors and further, that ginsenosides as well as ginsenoside metabolites can influence 5-HT3A receptor channel activity in Xenopus oocytes.	Ginsenosides	118-130	5-hydroxytryptamine receptor 3A	Homo sapiens	180-186
14760130-2	2004	Palonosetron, a potent and highly selective 5-HT3 antagonist with a strong affinity for 5-HT3 and a prolonged plasma elimination half-life, may provide a longer duration of action than other approved agents.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	44-49
14760130-2	2004	Palonosetron, a potent and highly selective 5-HT3 antagonist with a strong affinity for 5-HT3 and a prolonged plasma elimination half-life, may provide a longer duration of action than other approved agents.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	88-93
15123883-3	2004	A high proportion of tsA-201 cells cotransfected with the cDNAs of 5-HT(3)R and CD8 produced large amplitude responses (0.57.0 nA) to serotonin.	Serotonin	134-143	5-hydroxytryptamine receptor 3A	Homo sapiens	67-75
15123883-5	2004	Lysine at position 281, a basic residue, is more susceptible to acidification-induced blockade of the 5-HT(3)R channel.	Lysine	0-6	5-hydroxytryptamine receptor 3A	Homo sapiens	102-110
12970351-0	2003	Arginine 222 in the pre-transmembrane domain 1 of 5-HT3A receptors links agonist binding to channel gating.	Arginine	0-8	5-hydroxytryptamine receptor 3A	Homo sapiens	50-56
14636070-3	2003	The secondary structure of detergent-solubilized 5-HT(3)R determined by curve fitting of the amide I band yielded 36% alpha-helix, 33% beta-strand, 15% beta-turn, and 16% nonregular structures, which remained unchanged upon reconstitution in lipid membranes.	Amides	93-98	5-hydroxytryptamine receptor 3A	Homo sapiens	49-57
14636070-4	2003	From hydrogen-deuterium exchange, the secondary structure of the water-accessible part of 5-HT(3)R was determined as 14% alpha-helix, 16% beta-strand, 26% beta-turn, and 14% nonregular structures.	Hydrogen	5-13	5-hydroxytryptamine receptor 3A	Homo sapiens	90-98
14636070-4	2003	From hydrogen-deuterium exchange, the secondary structure of the water-accessible part of 5-HT(3)R was determined as 14% alpha-helix, 16% beta-strand, 26% beta-turn, and 14% nonregular structures.	Deuterium	14-23	5-hydroxytryptamine receptor 3A	Homo sapiens	90-98
14636070-4	2003	From hydrogen-deuterium exchange, the secondary structure of the water-accessible part of 5-HT(3)R was determined as 14% alpha-helix, 16% beta-strand, 26% beta-turn, and 14% nonregular structures.	Water	65-70	5-hydroxytryptamine receptor 3A	Homo sapiens	90-98
12970351-4	2003	Arginine 222 (Arg-222), located at the distal end of the extracellular N-terminal domain immediately preceding the first transmembrane domain (TM1), is conserved in all 5-HT3A receptors and alpha7-nicotinic acetylcholine receptors that have been cloned.	Arginine	0-8	5-hydroxytryptamine receptor 3A	Homo sapiens	169-175
12970351-4	2003	Arginine 222 (Arg-222), located at the distal end of the extracellular N-terminal domain immediately preceding the first transmembrane domain (TM1), is conserved in all 5-HT3A receptors and alpha7-nicotinic acetylcholine receptors that have been cloned.	Arginine	0-3	5-hydroxytryptamine receptor 3A	Homo sapiens	169-175
12970351-5	2003	To elucidate the possible role of Arg-222 in the function of 5-HT3A receptors, we mutated the arginine residue to alanine (Ala) and expressed both the wild-type and the mutant receptor in human embryonic kidney 293 cells.	Arginine	34-37	5-hydroxytryptamine receptor 3A	Homo sapiens	61-67
12970351-10	2003	The results suggest that the pre-TM1 amino acid residue Arg-222 may be involved in the transduction mechanism linking agonist binding to channel gating in 5-HT3A receptors.	Arginine	56-59	5-hydroxytryptamine receptor 3A	Homo sapiens	155-161
12660235-3	2003	To investigate the role of particular residues in ligand binding of the serotonin 5-HT3AS receptor (5-HT3R), glutamate amino acid residues at three different positions, Glu97, Glu224, and Glu235, in the extracellular N-terminal domain were substituted with aspartate and glutamine using site-directed mutagenesis.	Aspartic Acid	257-266	5-hydroxytryptamine receptor 3A	Homo sapiens	100-106
12867984-7	2003	Replacement of three arginine residues unique to the HA-stretch of the 5-HT3A subunit by their 5-HT3B subunit counterparts increased single-channel conductance 28-fold.	Arginine	21-29	5-hydroxytryptamine receptor 3A	Homo sapiens	71-77
12867984-9	2003	Our findings solve the conundrum of the anomalously low conductance of homomeric 5-HT3A receptors and indicate an important function for the HA-stretch in Cys-loop transmitter-gated ion channels.	Cysteine	155-158	5-hydroxytryptamine receptor 3A	Homo sapiens	81-87
12660235-3	2003	To investigate the role of particular residues in ligand binding of the serotonin 5-HT3AS receptor (5-HT3R), glutamate amino acid residues at three different positions, Glu97, Glu224, and Glu235, in the extracellular N-terminal domain were substituted with aspartate and glutamine using site-directed mutagenesis.	Glutamine	271-280	5-hydroxytryptamine receptor 3A	Homo sapiens	100-106
12660235-5	2003	A structural model of the ligand-binding domain of the 5-HT3R based on the acetylcholine binding protein revealed the position of the mutated amino acids.	Acetylcholine	75-88	5-hydroxytryptamine receptor 3A	Homo sapiens	55-61
12660235-8	2003	Comparison of the fluorescence properties of a fluorescein-labeled antagonist upon binding to wild type 5-HT3R and E235Q, allowed us to localize Glu235 within a distance of 1 nm around the ligand-binding site, as proposed by our model.	Fluorescein	47-58	5-hydroxytryptamine receptor 3A	Homo sapiens	104-110
12217367-1	2002	Electrostatic potential surface mapping of various aromatic ring systems contained in 5-HT(3)R agonists indicate that some agonists contain an aromatic moiety capable of a favorable cation-pi interaction next to the e-face of pyridine (or its bioisostere).	pyridine	226-234	5-hydroxytryptamine receptor 3A	Homo sapiens	86-94
12643925-0	2003	Conformationally-restricted analogues and partition coefficients of the 5-HT3 serotonin receptor ligands meta-chlorophenylbiguanide (mCPBG) and meta-chlorophenylguanidine (mCPG).	meta-chlorophenylbiguanide	105-131	5-hydroxytryptamine receptor 3A	Homo sapiens	72-96
12643925-0	2003	Conformationally-restricted analogues and partition coefficients of the 5-HT3 serotonin receptor ligands meta-chlorophenylbiguanide (mCPBG) and meta-chlorophenylguanidine (mCPG).	1-(3-chlorophenyl)biguanide	133-138	5-hydroxytryptamine receptor 3A	Homo sapiens	72-96
12643925-0	2003	Conformationally-restricted analogues and partition coefficients of the 5-HT3 serotonin receptor ligands meta-chlorophenylbiguanide (mCPBG) and meta-chlorophenylguanidine (mCPG).	meta-chlorophenylguanidine	144-170	5-hydroxytryptamine receptor 3A	Homo sapiens	72-96
12643925-0	2003	Conformationally-restricted analogues and partition coefficients of the 5-HT3 serotonin receptor ligands meta-chlorophenylbiguanide (mCPBG) and meta-chlorophenylguanidine (mCPG).	2-amino-2-(2-methylenecyclopropyl)acetic acid	172-176	5-hydroxytryptamine receptor 3A	Homo sapiens	72-96
12363396-8	2002	These results make unlikely the possibility that 5-HT3A and 5-HT3B receptor genes underlie variation in clinical response to clozapine.	Clozapine	125-134	5-hydroxytryptamine receptor 3A	Homo sapiens	49-55
12360456-1	2002	BACKGROUND & AIMS: The 5-HT3 receptor (5-HT3R) antagonist Alosetron (Alos) reduces the symptoms of female patients with diarrhea-predominant irritable bowel syndrome (IBS); yet, the mechanism(s) underlying this effect remains incompletely understood.	alosetron	62-71	5-hydroxytryptamine receptor 3A	Homo sapiens	27-41
12360456-1	2002	BACKGROUND & AIMS: The 5-HT3 receptor (5-HT3R) antagonist Alosetron (Alos) reduces the symptoms of female patients with diarrhea-predominant irritable bowel syndrome (IBS); yet, the mechanism(s) underlying this effect remains incompletely understood.	alosetron	62-71	5-hydroxytryptamine receptor 3A	Homo sapiens	43-49
12360456-1	2002	BACKGROUND & AIMS: The 5-HT3 receptor (5-HT3R) antagonist Alosetron (Alos) reduces the symptoms of female patients with diarrhea-predominant irritable bowel syndrome (IBS); yet, the mechanism(s) underlying this effect remains incompletely understood.	alosetron	62-66	5-hydroxytryptamine receptor 3A	Homo sapiens	27-41
12360456-1	2002	BACKGROUND & AIMS: The 5-HT3 receptor (5-HT3R) antagonist Alosetron (Alos) reduces the symptoms of female patients with diarrhea-predominant irritable bowel syndrome (IBS); yet, the mechanism(s) underlying this effect remains incompletely understood.	alosetron	62-66	5-hydroxytryptamine receptor 3A	Homo sapiens	43-49
12360456-0	2002	Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.	alosetron	78-87	5-hydroxytryptamine receptor 3A	Homo sapiens	52-66
12360456-8	2002	RESULTS: Alos treatment, as compared with placebo, improved IBS symptoms and reduced rCBF in 5-HT3R containing regions of the EMS, but not in areas activated by pain.	alosetron	9-13	5-hydroxytryptamine receptor 3A	Homo sapiens	93-99
11495906-10	2001	Of the 20 proline residues in the 5-HT3A receptor subunit only Pro170 has adjacent residues that are favorable.	Proline	10-17	5-hydroxytryptamine receptor 3A	Homo sapiens	34-40
12079499-1	2002	BACKGROUND: Lerisetron, a competitive serotonin type 3 receptor (5-HT3R) antagonist, contains five functional groups capable of interacting with amino acids in the 5-HT3R binding site.	lerisetron	12-22	5-hydroxytryptamine receptor 3A	Homo sapiens	65-71
12079499-1	2002	BACKGROUND: Lerisetron, a competitive serotonin type 3 receptor (5-HT3R) antagonist, contains five functional groups capable of interacting with amino acids in the 5-HT3R binding site.	lerisetron	12-22	5-hydroxytryptamine receptor 3A	Homo sapiens	164-170
12079499-5	2002	RESULTS: Two analogs of lerisetron were synthesized to probe 5-HT3R functional group interactions with this compound.	lerisetron	24-34	5-hydroxytryptamine receptor 3A	Homo sapiens	61-67
11259629-2	2001	Using the whole-cell voltage-clamp technique, we investigated desensitization kinetics of recombinant human and guinea pig alpha-homomeric 5-hydroxytryptamine type 3 (5-HT(3A)) receptors heterologously expressed in human embryonic kidney 293 cells.	Serotonin	139-158	5-hydroxytryptamine receptor 3A	Homo sapiens	167-174
11762972-2	2001	This is particularly relevant with the high-cost 5HT3 antiemetics, which include ondansetron, dolasetron and granisetron.	Ondansetron	81-92	5-hydroxytryptamine receptor 3A	Homo sapiens	49-53
11762972-2	2001	This is particularly relevant with the high-cost 5HT3 antiemetics, which include ondansetron, dolasetron and granisetron.	dolasetron	94-104	5-hydroxytryptamine receptor 3A	Homo sapiens	49-53
11762972-2	2001	This is particularly relevant with the high-cost 5HT3 antiemetics, which include ondansetron, dolasetron and granisetron.	Granisetron	109-120	5-hydroxytryptamine receptor 3A	Homo sapiens	49-53
11557597-6	2001	Application of the 5-HT (5-150 microM) and 5-HT(3)-R agonist 2-methyl-5-HT (5-150 microM) induced inward currents in a concentration-dependent manner.	2-methyl-5-HT	61-74	5-hydroxytryptamine receptor 3A	Homo sapiens	43-52
11259629-4	2001	By constructing various chimeras and through site-directed mutagenesis, we have identified a single serine in the M1 region of the human 5-HT(3A) receptor sequence (S248) that, when substituted with threonine found in the equivalent guinea pig sequence (T254), conferred guinea pig-like kinetics on the time course of desensitization of the human receptor.	Serine	100-106	5-hydroxytryptamine receptor 3A	Homo sapiens	137-144
11259629-4	2001	By constructing various chimeras and through site-directed mutagenesis, we have identified a single serine in the M1 region of the human 5-HT(3A) receptor sequence (S248) that, when substituted with threonine found in the equivalent guinea pig sequence (T254), conferred guinea pig-like kinetics on the time course of desensitization of the human receptor.	Threonine	199-208	5-hydroxytryptamine receptor 3A	Homo sapiens	137-144
11111833-1	2000	Serotonin (5-HT) exerts fast excitatory responses by activation of 5-HT3 receptors, irrespective of whether they are homomerically composed of 5-HT3A subunits or heteromerically assembled of 5-HT3A and 5-HT3B subunits.	Serotonin	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	191-197
11212100-0	2001	The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.	Tropisetron	21-32	5-hydroxytryptamine receptor 3A	Homo sapiens	4-9
11212100-1	2001	The 5-HT3 receptor antagonist tropisetron (ICS 205-930) was found to be a potent and selective partial agonist at alpha7 nicotinic receptors.	Tropisetron	30-41	5-hydroxytryptamine receptor 3A	Homo sapiens	4-9
11212100-2	2001	Two other 5-HT3 receptor antagonists, ondansetron and LY-278,584, were found to lack high affinity at the alpha7 nicotinic receptor.	Ondansetron	38-49	5-hydroxytryptamine receptor 3A	Homo sapiens	10-15
11212100-2	2001	Two other 5-HT3 receptor antagonists, ondansetron and LY-278,584, were found to lack high affinity at the alpha7 nicotinic receptor.	ly-278	54-60	5-hydroxytryptamine receptor 3A	Homo sapiens	10-15
10997728-0	2000	Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects.	barbituric acid	97-108	5-hydroxytryptamine receptor 3A	Homo sapiens	18-24
10997728-4	2000	The 5-HT3A receptor antagonist ondansetron (0.3 nM) reversibly inhibited the 5-HT (30 microM) signal by 70% and at 3 nM it abolished the response.	Ondansetron	31-42	5-hydroxytryptamine receptor 3A	Homo sapiens	4-10
10608286-1	1999	In order to study the subunit composition of 5-HT3 receptors (5-HT3R), we report that (2-aminoethyl)methanethiosulfonate (MTSEA) can enhance the function of both nicotinic ACh receptors (nAChRs) comprised of alpha4/beta2 subunits, and heteromeric channels assembled from serotonin 5-HT3R and alpha4 nAChR subunits.	methanethiosulfonate ethylammonium	86-120	5-hydroxytryptamine receptor 3A	Homo sapiens	45-60
10639097-2	2000	Uniquely, 5-HT3 receptor subunits (5-HT3A and 5-HT3B) possess a positively charged lysine residue within the putative channel lining M2 domain (4" position).	Lysine	83-89	5-hydroxytryptamine receptor 3A	Homo sapiens	35-41
10639097-8	2000	Each of the mutants desensitized more slowly than the WT 5-HT3A receptor, with the arginine and glycine mutations exhibiting the greatest effect (5-fold reduction).	Arginine	83-91	5-hydroxytryptamine receptor 3A	Homo sapiens	57-63
10639097-8	2000	Each of the mutants desensitized more slowly than the WT 5-HT3A receptor, with the arginine and glycine mutations exhibiting the greatest effect (5-fold reduction).	Glycine	96-103	5-hydroxytryptamine receptor 3A	Homo sapiens	57-63
10608286-1	1999	In order to study the subunit composition of 5-HT3 receptors (5-HT3R), we report that (2-aminoethyl)methanethiosulfonate (MTSEA) can enhance the function of both nicotinic ACh receptors (nAChRs) comprised of alpha4/beta2 subunits, and heteromeric channels assembled from serotonin 5-HT3R and alpha4 nAChR subunits.	methanethiosulfonate ethylammonium	86-120	5-hydroxytryptamine receptor 3A	Homo sapiens	62-68
10608286-1	1999	In order to study the subunit composition of 5-HT3 receptors (5-HT3R), we report that (2-aminoethyl)methanethiosulfonate (MTSEA) can enhance the function of both nicotinic ACh receptors (nAChRs) comprised of alpha4/beta2 subunits, and heteromeric channels assembled from serotonin 5-HT3R and alpha4 nAChR subunits.	methanethiosulfonate ethylammonium	86-120	5-hydroxytryptamine receptor 3A	Homo sapiens	281-287
10026168-4	1999	Comparison of the sequences of these two subunits with the 5HT3R shows that a tryptophan residue is found in the homologous position in the 5HT3R (Trp-89), suggesting that this residue may be involved in curare-5HT3R interactions.	Tryptophan	78-88	5-hydroxytryptamine receptor 3A	Homo sapiens	59-64
10347245-6	1999	The magnitude of the shift increased with the number of residues (3, 5, or 7) exchanged, with septuple mutations of m5-HT3A and human 5-HT3A subunits producing a 161-fold decrease and 53-fold increase in the apparent affinity of (+)-Tc, respectively.	Technetium	229-235	5-hydroxytryptamine receptor 3A	Homo sapiens	117-123
10026168-4	1999	Comparison of the sequences of these two subunits with the 5HT3R shows that a tryptophan residue is found in the homologous position in the 5HT3R (Trp-89), suggesting that this residue may be involved in curare-5HT3R interactions.	Tryptophan	78-88	5-hydroxytryptamine receptor 3A	Homo sapiens	140-145
10026168-4	1999	Comparison of the sequences of these two subunits with the 5HT3R shows that a tryptophan residue is found in the homologous position in the 5HT3R (Trp-89), suggesting that this residue may be involved in curare-5HT3R interactions.	Tryptophan	78-88	5-hydroxytryptamine receptor 3A	Homo sapiens	140-145
10026168-4	1999	Comparison of the sequences of these two subunits with the 5HT3R shows that a tryptophan residue is found in the homologous position in the 5HT3R (Trp-89), suggesting that this residue may be involved in curare-5HT3R interactions.	Tryptophan	147-150	5-hydroxytryptamine receptor 3A	Homo sapiens	59-64
10026168-4	1999	Comparison of the sequences of these two subunits with the 5HT3R shows that a tryptophan residue is found in the homologous position in the 5HT3R (Trp-89), suggesting that this residue may be involved in curare-5HT3R interactions.	Tryptophan	147-150	5-hydroxytryptamine receptor 3A	Homo sapiens	140-145
10026168-4	1999	Comparison of the sequences of these two subunits with the 5HT3R shows that a tryptophan residue is found in the homologous position in the 5HT3R (Trp-89), suggesting that this residue may be involved in curare-5HT3R interactions.	Tryptophan	147-150	5-hydroxytryptamine receptor 3A	Homo sapiens	140-145
10026168-5	1999	Site-directed mutagenesis at position Trp-89 markedly reduces the affinity of the 5HT3R for the antagonists curare and granisetron but has little effect on the affinity for the agonist serotonin.	Tryptophan	38-41	5-hydroxytryptamine receptor 3A	Homo sapiens	82-87
9950429-7	1999	Heteromeric assemblies of 5-HT3A and 5-HT3B subunits display a large single-channel conductance (16 pS), low permeability to calcium ions, and a current-voltage relationship which resembles that of characterized neuronal 5-HT3 channels.	Calcium	125-132	5-hydroxytryptamine receptor 3A	Homo sapiens	26-32
9933581-8	1999	To test the hypothesis that the alpha4 subunit contributes to the lining of the pore of the resulting 5-HT3R channel, a mutant nicotinic alpha4 subunit with a reactive cysteine residue engineered into the putative pore region was constructed by substituting the leucine at position 285 (alpha4-L285C).	Cysteine	168-176	5-hydroxytryptamine receptor 3A	Homo sapiens	102-108
9933581-8	1999	To test the hypothesis that the alpha4 subunit contributes to the lining of the pore of the resulting 5-HT3R channel, a mutant nicotinic alpha4 subunit with a reactive cysteine residue engineered into the putative pore region was constructed by substituting the leucine at position 285 (alpha4-L285C).	Leucine	262-269	5-hydroxytryptamine receptor 3A	Homo sapiens	102-108
9933581-10	1999	When the alpha4-L285C subunit was co-expressed with the 5-HT3R subunit, both MTSET and silver nitrate (AgNO3), another cysteine-modifying reagent, significantly reduced the serotonin-induced current.	Silver Nitrate	87-101	5-hydroxytryptamine receptor 3A	Homo sapiens	56-62
9933581-10	1999	When the alpha4-L285C subunit was co-expressed with the 5-HT3R subunit, both MTSET and silver nitrate (AgNO3), another cysteine-modifying reagent, significantly reduced the serotonin-induced current.	Silver Nitrate	103-108	5-hydroxytryptamine receptor 3A	Homo sapiens	56-62
9933581-10	1999	When the alpha4-L285C subunit was co-expressed with the 5-HT3R subunit, both MTSET and silver nitrate (AgNO3), another cysteine-modifying reagent, significantly reduced the serotonin-induced current.	Cysteine	119-127	5-hydroxytryptamine receptor 3A	Homo sapiens	56-62
9933581-10	1999	When the alpha4-L285C subunit was co-expressed with the 5-HT3R subunit, both MTSET and silver nitrate (AgNO3), another cysteine-modifying reagent, significantly reduced the serotonin-induced current.	Serotonin	173-182	5-hydroxytryptamine receptor 3A	Homo sapiens	56-62
9164590-0	1997	Effects of 5-HT3, D1 and D2 receptor antagonists on ethanol- and cocaine-induced locomotion.	Ethanol	52-59	5-hydroxytryptamine receptor 3A	Homo sapiens	11-16
9680250-1	1998	D-Tubocurarine is a potent competitive antagonist of two members of the ligand-gated ion channel family, the muscle-type nicotinic acetylcholine receptor (AChR) and serotonin type-3 receptor (5HT3R).	Tubocurarine	0-14	5-hydroxytryptamine receptor 3A	Homo sapiens	192-197
9680250-2	1998	We have used a series of analogs of D-tubocurarine to determine the effects of methylation, stereoisomerization and halogenation on the interaction of D-tubocurarine with the 5HT3R.	Tubocurarine	36-50	5-hydroxytryptamine receptor 3A	Homo sapiens	175-180
9680250-2	1998	We have used a series of analogs of D-tubocurarine to determine the effects of methylation, stereoisomerization and halogenation on the interaction of D-tubocurarine with the 5HT3R.	Tubocurarine	151-165	5-hydroxytryptamine receptor 3A	Homo sapiens	175-180
9736758-1	1998	Serotonin (5-hydroxytryptamine) type 3 receptors (5-HT3R) and nicotinic acetylcholine receptors are structurally and functionally related proteins, yet distinct members of the family of ligand-gated ion channels.	Serotonin	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	50-56
9164590-0	1997	Effects of 5-HT3, D1 and D2 receptor antagonists on ethanol- and cocaine-induced locomotion.	Cocaine	65-72	5-hydroxytryptamine receptor 3A	Homo sapiens	11-16
9164590-1	1997	The effects of acute treatment with 5-HT3 receptor antagonists, ondansetron and ICS 205-930, on the stimulation of activity induced by ethanol-and cocaine were examined.	Ethanol	135-142	5-hydroxytryptamine receptor 3A	Homo sapiens	36-41
9164590-1	1997	The effects of acute treatment with 5-HT3 receptor antagonists, ondansetron and ICS 205-930, on the stimulation of activity induced by ethanol-and cocaine were examined.	Cocaine	147-154	5-hydroxytryptamine receptor 3A	Homo sapiens	36-41
22298739-0	1995	The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man.	Ondansetron	21-32	5-hydroxytryptamine receptor 3A	Homo sapiens	4-9
8636782-4	1996	PATIENTS AND METHODS: We applied a novel statistical approach to investigate whether the efficacy of the 5HT3 receptor antagonist ICS 205-930 (tropisetron) is maintained over repeated cycles of weekly high-dose cisplatin.	Cisplatin	211-220	5-hydroxytryptamine receptor 3A	Homo sapiens	105-109
8848005-5	1995	A quantitative comparison of the pharmacological profiles of human and mouse recombinant 5-HT3R-AS receptor complexes revealed differences in the potencies of some antagonist or agonist compounds tested, the most dramatic example being (+)-tubocurarine, which demonstrated an approximately 1800-fold discrepancy in antagonist potency.	Tubocurarine	236-252	5-hydroxytryptamine receptor 3A	Homo sapiens	89-95
8856622-0	1996	Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome--a preliminary study.	Ondansetron	42-53	5-hydroxytryptamine receptor 3A	Homo sapiens	55-90
8856622-1	1996	OBJECTIVE: To study the efficacy of 5-hydroxytryptamine type 3 receptor (5-HT-3R) antagonist (ondansetron) vs paracetamol in primary fibromyalgia (FM) syndrome.	Ondansetron	94-105	5-hydroxytryptamine receptor 3A	Homo sapiens	36-71
8856622-1	1996	OBJECTIVE: To study the efficacy of 5-hydroxytryptamine type 3 receptor (5-HT-3R) antagonist (ondansetron) vs paracetamol in primary fibromyalgia (FM) syndrome.	Ondansetron	94-105	5-hydroxytryptamine receptor 3A	Homo sapiens	73-80
9455457-2	1996	This issue is a clinical analysis of the protective effect of a 5HT3 antagonist (Navoban-R; Sandoz Pharma Ltd., Basel, Switzerland) against chemotherapy--induced emesis (especially with the most emetic cytostatics--cisplatin and dacarbazine).	navoban-r	81-90	5-hydroxytryptamine receptor 3A	Homo sapiens	64-68
9455457-2	1996	This issue is a clinical analysis of the protective effect of a 5HT3 antagonist (Navoban-R; Sandoz Pharma Ltd., Basel, Switzerland) against chemotherapy--induced emesis (especially with the most emetic cytostatics--cisplatin and dacarbazine).	Cisplatin	215-224	5-hydroxytryptamine receptor 3A	Homo sapiens	64-68
9455457-2	1996	This issue is a clinical analysis of the protective effect of a 5HT3 antagonist (Navoban-R; Sandoz Pharma Ltd., Basel, Switzerland) against chemotherapy--induced emesis (especially with the most emetic cytostatics--cisplatin and dacarbazine).	Dacarbazine	229-240	5-hydroxytryptamine receptor 3A	Homo sapiens	64-68
8991800-0	1995	Effects of granisetron, a 5-HT3 receptor antagonist, on morphine-induced potentiation of brain stimulation reward.	Granisetron	11-22	5-hydroxytryptamine receptor 3A	Homo sapiens	26-31
7565620-11	1995	Transfection of COS-1 with human 5-HT3R cDNA induced specific binding of the 5-HT3R-selective radioligand [3H]YM060.	Tritium	107-109	5-hydroxytryptamine receptor 3A	Homo sapiens	33-39
7565620-11	1995	Transfection of COS-1 with human 5-HT3R cDNA induced specific binding of the 5-HT3R-selective radioligand [3H]YM060.	Tritium	107-109	5-hydroxytryptamine receptor 3A	Homo sapiens	77-83
7565620-12	1995	Human 5-HT3R showed typical characteristics of the 5-HT3R, but its affinity for the 5-HT3R agonist m-chlorophenylbiguanide was much lower than that of rat 5-HT3R.	1-(3-chlorophenyl)biguanide	99-122	5-hydroxytryptamine receptor 3A	Homo sapiens	6-12
7565620-14	1995	The potency of the agonists to induce inward current paralleled that to compete with the radioligand binding, and 2-methyl-5-hydroxytryptamine, a partial agonist for mouse 5-HT3R, was a full agonist for human 5-HT3R.	2-methyl-5-HT	114-142	5-hydroxytryptamine receptor 3A	Homo sapiens	209-215
22298739-0	1995	The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man.	Serotonin	93-102	5-hydroxytryptamine receptor 3A	Homo sapiens	4-9
7993957-1	1994	Results from animal studies have suggested that serotonin (5-HT) antagonists acting on the 5-HT3 receptor may have anxiolytic properties.	Serotonin	48-57	5-hydroxytryptamine receptor 3A	Homo sapiens	91-96
7808432-2	1994	The selective 5-HT3 receptor agonist 1-(m-chlorophenyl)-biguanide (mCPBG) caused a concentration-dependent increase in the cytoplasmic Ca2+ concentration ([Ca2+]i) in N1E-115 cells and in HEK 293 cells transfected with either the 5-HT3 A subunit or the 5-HT3 As subunit.	1-(3-chlorophenyl)biguanide	37-65	5-hydroxytryptamine receptor 3A	Homo sapiens	230-237
7808432-2	1994	The selective 5-HT3 receptor agonist 1-(m-chlorophenyl)-biguanide (mCPBG) caused a concentration-dependent increase in the cytoplasmic Ca2+ concentration ([Ca2+]i) in N1E-115 cells and in HEK 293 cells transfected with either the 5-HT3 A subunit or the 5-HT3 As subunit.	1-(3-chlorophenyl)biguanide	67-72	5-hydroxytryptamine receptor 3A	Homo sapiens	230-237
7993957-2	1994	We have assessed whether pretreatment with the 5-HT3 receptor antagonist BRL 46470 (1 mg orally) attenuates the increase in anxiety induced in healthy volunteers by intravenous infusion of m-chlorophenylpiperazine (mCPP: 0.08 mg/kg over 2 min).	BRL 46470	73-82	5-hydroxytryptamine receptor 3A	Homo sapiens	47-52
7993957-2	1994	We have assessed whether pretreatment with the 5-HT3 receptor antagonist BRL 46470 (1 mg orally) attenuates the increase in anxiety induced in healthy volunteers by intravenous infusion of m-chlorophenylpiperazine (mCPP: 0.08 mg/kg over 2 min).	1-(3-chlorophenyl)piperazine	189-213	5-hydroxytryptamine receptor 3A	Homo sapiens	47-52
7993957-2	1994	We have assessed whether pretreatment with the 5-HT3 receptor antagonist BRL 46470 (1 mg orally) attenuates the increase in anxiety induced in healthy volunteers by intravenous infusion of m-chlorophenylpiperazine (mCPP: 0.08 mg/kg over 2 min).	1-(3-chlorophenyl)piperazine	215-219	5-hydroxytryptamine receptor 3A	Homo sapiens	47-52
8032707-1	1994	Granisetron, a potent and selective 5-hydroxytryptamine receptor (5-HT3) antagonist was reported to be an effective antiemetic agent both in animal studies and in patients given highly emetogenic chemotherapy.	Granisetron	0-11	5-hydroxytryptamine receptor 3A	Homo sapiens	66-71
7919451-1	1994	This review discusses the development and use of 5-hydroxytryptamine3 (5-HT3) antagonists, especially granisetron, for the treatment of chemotherapy-induced emesis.	5-hydroxytryptamine3	49-69	5-hydroxytryptamine receptor 3A	Homo sapiens	71-76
7919451-1	1994	This review discusses the development and use of 5-hydroxytryptamine3 (5-HT3) antagonists, especially granisetron, for the treatment of chemotherapy-induced emesis.	Granisetron	102-113	5-hydroxytryptamine receptor 3A	Homo sapiens	71-76
7919451-3	1994	Granisetron, a new 5-HT3, is approximately 400 times more potent than metoclopramide and, unlike metoclopramide, does not produce extrapyramidal side effects.	Granisetron	0-11	5-hydroxytryptamine receptor 3A	Homo sapiens	19-24
7690681-2	1993	Acute phase (0-24 hours after induction of chemotherapy) nausea and vomiting parallels plasma serotonin release, which explains the effectiveness of 5HT3 antagonists; serotonin release in the delayed phase (24-48 hours after induction), during which consistent antiemetic control remains elusive, has not been investigated.	Serotonin	94-103	5-hydroxytryptamine receptor 3A	Homo sapiens	149-153
8299095-2	1994	Ondansetron is a potent and highly specific antagonist of the 5-HT3 serotonin receptor.	Ondansetron	0-11	5-hydroxytryptamine receptor 3A	Homo sapiens	62-86
2138064-2	1990	were given the 5HT3 antagonist Ondansetron (Glaxo) as an antiemetic.	Ondansetron	31-42	5-hydroxytryptamine receptor 3A	Homo sapiens	15-19
1838490-0	1991	[Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].	Ondansetron	1-12	5-hydroxytryptamine receptor 3A	Homo sapiens	25-49
2144721-0	1990	5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.	Ondansetron	17-28	5-hydroxytryptamine receptor 3A	Homo sapiens	0-5
2144721-1	1990	Thirty children aged 2-16 years with malignant tumours who were receiving chemotherapy were treated with the 5-HT3 antagonist ondansetron.	Ondansetron	126-137	5-hydroxytryptamine receptor 3A	Homo sapiens	109-114
8347903-4	1993	DATA SYNTHESIS: Ondansetron, a potent and highly selective antagonist of serotonin at the 5-HT3 (subtype 3)-receptor, possesses potent antiemetic effects.	Ondansetron	16-27	5-hydroxytryptamine receptor 3A	Homo sapiens	90-116
8347903-4	1993	DATA SYNTHESIS: Ondansetron, a potent and highly selective antagonist of serotonin at the 5-HT3 (subtype 3)-receptor, possesses potent antiemetic effects.	Serotonin	73-82	5-hydroxytryptamine receptor 3A	Homo sapiens	90-116
7678181-7	1993	The effect of serotonin was mediated by 5-HT1A-type serotonin receptors (5-HT1AR) as indicated by mimicry exerted by 5-HT1AR agonists such as 8-OH-DPAT and (+)-ALK, partial antagonism by the 5-HT1AR antagonists pindolol and cyproheptadine, and lack of antagonism by the 5-HT2R antagonist ketanserin or the 5-HT3R antagonist ondansetron.	Serotonin	14-23	5-hydroxytryptamine receptor 3A	Homo sapiens	306-312
33807811-3	2021	The present study investigated the association of nine polymorphisms in the four 5-hydroxytryptamine receptor (HTR) genes HTR1A, HTR2A, HTR3A, and HTR2C and the gene encoding for the serotonin transporter SLC6A4 with MetS in patients with schizophrenia.	Serotonin	81-100	5-hydroxytryptamine receptor 3A	Homo sapiens	136-141
1831542-0	1990	Evaluation of the 5HT3 antagonist ondansetron (O) for cocaine (C)-like activity and abuse potential.	Ondansetron	34-45	5-hydroxytryptamine receptor 3A	Homo sapiens	18-22
33767348-7	2021	To gain further translational insights, we revealed that combined treatment of zonisamide (enhancing the GABAAR-alpha5 signaling) and granisetron (a selective 5-HT3R antagonist) alleviates mental dysfunction and yields a robust reversal of diet-induced obesity by reducing total calorie intake and altering food preference towards a healthy low-fat diet.	Zonisamide	79-89	5-hydroxytryptamine receptor 3A	Homo sapiens	159-165
33767348-7	2021	To gain further translational insights, we revealed that combined treatment of zonisamide (enhancing the GABAAR-alpha5 signaling) and granisetron (a selective 5-HT3R antagonist) alleviates mental dysfunction and yields a robust reversal of diet-induced obesity by reducing total calorie intake and altering food preference towards a healthy low-fat diet.	Granisetron	134-145	5-hydroxytryptamine receptor 3A	Homo sapiens	159-165
33807811-3	2021	The present study investigated the association of nine polymorphisms in the four 5-hydroxytryptamine receptor (HTR) genes HTR1A, HTR2A, HTR3A, and HTR2C and the gene encoding for the serotonin transporter SLC6A4 with MetS in patients with schizophrenia.	Serotonin	183-192	5-hydroxytryptamine receptor 3A	Homo sapiens	136-141
34467765-1	2021	In line with recent clinical trials demonstrating that ondansetron, a 5-HT3 receptor (5-HT3R) antagonist, ameliorates cognitive deficits of schizophrenia and the known procognitive effects of 5-HT6 receptor (5-HT6R) antagonists, we applied the hybridization strategy to design dual-acting 5-HT3/5-HT6R antagonists.	Ondansetron	55-66	5-hydroxytryptamine receptor 3A	Homo sapiens	70-84
34667294-1	2022	Serotonin type-3 receptor (5-HT3R) antagonists show potential as a treatment for cognitive deficits in schizophrenia.	Serotonin	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	27-33
34467765-1	2021	In line with recent clinical trials demonstrating that ondansetron, a 5-HT3 receptor (5-HT3R) antagonist, ameliorates cognitive deficits of schizophrenia and the known procognitive effects of 5-HT6 receptor (5-HT6R) antagonists, we applied the hybridization strategy to design dual-acting 5-HT3/5-HT6R antagonists.	Ondansetron	55-66	5-hydroxytryptamine receptor 3A	Homo sapiens	86-92
34467765-2	2021	We identified the first-in-class compound FPPQ, which behaves as a 5-HT3R antagonist and a neutral antagonist 5-HT6R of the Gs pathway.	FPPQ	42-46	5-hydroxytryptamine receptor 3A	Homo sapiens	67-73
34467765-6	2021	Thus, combination of 5-HT3R antagonism and 5-HT6R antagonism, exemplified by FPPQ, contributes to alleviating the positive-like symptoms.	FPPQ	77-81	5-hydroxytryptamine receptor 3A	Homo sapiens	21-27
34285037-5	2021	CRC cell-originated 5-HT enhanced NLRP3 inflammasome activation in THP-1 cells and immortalized bone marrow-derived macrophages (iBMDM) via its ion channel receptor, HTR3A.	Serotonin	20-24	5-hydroxytryptamine receptor 3A	Homo sapiens	166-171
2525078-1	1989	The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide.	Ondansetron	35-43	5-hydroxytryptamine receptor 3A	Homo sapiens	10-14
34202161-4	2021	To discover candidate genes involved in PG neurogenesis, the transcriptome profiling of sacral NC and developing PG was performed, and we identified the enrichment of the type 3 serotonin receptor (5-HT3, encoded by Htr3a and Htr3b).	Serotonin	178-187	5-hydroxytryptamine receptor 3A	Homo sapiens	216-221
34202161-5	2021	We determined that Htr3a is one of the first serotonin receptor genes that is up-regulated in sacral NC progenitors and is maintained in differentiating PG neurons.	Serotonin	45-54	5-hydroxytryptamine receptor 3A	Homo sapiens	19-24
34070942-10	2021	Overall, our data suggest that human parietal cells in culture, as well as from the gastric antrum, synthesize serotonin and release it after treatment with L-Arg via an HTR3-related mechanism.	Serotonin	111-120	5-hydroxytryptamine receptor 3A	Homo sapiens	170-174
34070942-10	2021	Overall, our data suggest that human parietal cells in culture, as well as from the gastric antrum, synthesize serotonin and release it after treatment with L-Arg via an HTR3-related mechanism.	Arginine	157-162	5-hydroxytryptamine receptor 3A	Homo sapiens	170-174
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	Serotonin	22-31	5-hydroxytryptamine receptor 3A	Homo sapiens	140-171
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	Serotonin	22-31	5-hydroxytryptamine receptor 3A	Homo sapiens	173-178
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	Serotonin	22-31	5-hydroxytryptamine receptor 3A	Homo sapiens	200-204
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	Serotonin	22-31	5-hydroxytryptamine receptor 3A	Homo sapiens	277-282
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	Serotonin	33-36	5-hydroxytryptamine receptor 3A	Homo sapiens	140-171
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	Serotonin	33-36	5-hydroxytryptamine receptor 3A	Homo sapiens	173-178
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	Serotonin	33-36	5-hydroxytryptamine receptor 3A	Homo sapiens	200-204
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	Serotonin	33-36	5-hydroxytryptamine receptor 3A	Homo sapiens	277-282
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	chromaffin	62-72	5-hydroxytryptamine receptor 3A	Homo sapiens	173-178
35614045-3	2022	Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor "bridge" cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists.	chromaffin	62-72	5-hydroxytryptamine receptor 3A	Homo sapiens	200-204
35017671-6	2022	A consistent and robust finding (five studies) was that ondansetron and tropisetron (5HT3 antagonist and alpha7-nicotinic receptor partial agonist) improved sensory gating in patients with schizophrenia.	Tropisetron	72-83	5-hydroxytryptamine receptor 3A	Homo sapiens	85-89
2529108-1	1989	Antagonists of 5-hydroxytryptamine type 3 (5HT3) receptors reduce the nausea induced by cisplatinum, but the effects of these agents on 5HT3 receptors in the human gut remain to be defined.	Cisplatin	88-99	5-hydroxytryptamine receptor 3A	Homo sapiens	43-47
35457612-0	2022	Serotonin Receptor HTR3A Gene Polymorphisms rs1985242 and rs1062613, E-Cigarette Use and Personality.	Serotonin	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	19-24
35457612-3	2022	In this study we analyzed two polymorphisms-rs1985242 and rs1062613-in the serotonin receptor HTR3A gene in a group of e-cigarette users (n = 135) and controls (n = 106).	Serotonin	75-84	5-hydroxytryptamine receptor 3A	Homo sapiens	94-99
2525078-1	1989	The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide.	Cyclophosphamide	98-114	5-hydroxytryptamine receptor 3A	Homo sapiens	10-14
2525078-1	1989	The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide.	Ifosfamide	124-134	5-hydroxytryptamine receptor 3A	Homo sapiens	10-14
2525078-5	1989	This selective 5HT3 antagonist is effective and safe in the control of ifosfamide-induced emesis, even in patients resistant to high-dose metoclopramide.	Ifosfamide	71-81	5-hydroxytryptamine receptor 3A	Homo sapiens	15-19
2525078-5	1989	This selective 5HT3 antagonist is effective and safe in the control of ifosfamide-induced emesis, even in patients resistant to high-dose metoclopramide.	Metoclopramide	138-152	5-hydroxytryptamine receptor 3A	Homo sapiens	15-19
33668306-3	2021	In this study, chanoclavine, which has a ring structure similar to 5-hydroxytryptamine (5-HT), showed an interaction with the 5-HT3A receptor to regulate IBS.	chanoclavine	15-27	5-hydroxytryptamine receptor 3A	Homo sapiens	126-132
33869168-2	2021	This study was aim to investigate the mechanism of bilirubin in cholestasis mediating pain desensitization through 5-hydroxytryptamine 3A (5-HT3A ) receptor activation in spinal dorsal horn (SDH).	Bilirubin	51-60	5-hydroxytryptamine receptor 3A	Homo sapiens	139-145
33869168-11	2021	Bilirubin also increased GABA concentrations in CSF and GABAergic spontaneous inhibitory postsynaptic current in spinal cord, and directly induced inward currents in HEK293 cells which were overexpressed 5-HT3A receptor by lentivirus.	Bilirubin	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	204-210
33869168-12	2021	Conclusion: In conclusion, bilirubin induced pain desensitization in cholestasis by activating 5-HT3A receptor in spinal cord.	Bilirubin	27-36	5-hydroxytryptamine receptor 3A	Homo sapiens	95-101
33869168-13	2021	The activation of 5-HT3A receptor might regulate pain threshold by acting on the GABA pathway.	gamma-Aminobutyric Acid	81-85	5-hydroxytryptamine receptor 3A	Homo sapiens	18-24
33668306-3	2021	In this study, chanoclavine, which has a ring structure similar to 5-hydroxytryptamine (5-HT), showed an interaction with the 5-HT3A receptor to regulate IBS.	Serotonin	67-86	5-hydroxytryptamine receptor 3A	Homo sapiens	126-132
33668306-3	2021	In this study, chanoclavine, which has a ring structure similar to 5-hydroxytryptamine (5-HT), showed an interaction with the 5-HT3A receptor to regulate IBS.	Serotonin	88-92	5-hydroxytryptamine receptor 3A	Homo sapiens	126-132
33668306-4	2021	Although its derivatives are known to be involved in neurotransmitter receptors, the molecular physiological mechanism of the interaction between chanoclavine and the 5-HT3A receptor is unknown.	chanoclavine	146-158	5-hydroxytryptamine receptor 3A	Homo sapiens	167-173
33668306-7	2021	The 5-HT3A response induced by 5-HT was blocked by chanoclavine with half-maximal inhibitory response concentration (IC50) values of 107.2 microM.	chanoclavine	51-63	5-hydroxytryptamine receptor 3A	Homo sapiens	4-10
33668306-8	2021	Docking studies suggested that chanoclavine was positioned close F130 and N138 in the 5-HT3A receptor-binding site.	chanoclavine	31-43	5-hydroxytryptamine receptor 3A	Homo sapiens	86-92
33668306-8	2021	Docking studies suggested that chanoclavine was positioned close F130 and N138 in the 5-HT3A receptor-binding site.	Bis[3-(triethoxysilyl)propyl]tetrasulfide	74-78	5-hydroxytryptamine receptor 3A	Homo sapiens	86-92
33668306-13	2021	The results of the electrophysiological studies and of in silico simulation showed that chanoclavine has the potential to inhibit the hypergastric stimulation of the gut by inhibiting the stimulation of signal transduction through 5-HT3A receptor stimulation.	chanoclavine	88-100	5-hydroxytryptamine receptor 3A	Homo sapiens	231-237
33594077-0	2021	Asymmetric opening of the homopentameric 5-HT3A serotonin receptor in lipid bilayers.	Lipid Bilayers	70-84	5-hydroxytryptamine receptor 3A	Homo sapiens	41-66
33594077-3	2021	We report three structures of the Cys-loop 5-HT3A serotonin receptor (5HT3R) reconstituted into saposin-based lipid bilayer discs: a symmetric and an asymmetric apo state, and an asymmetric agonist-bound state.	Cysteine	34-37	5-hydroxytryptamine receptor 3A	Homo sapiens	43-68
33594077-3	2021	We report three structures of the Cys-loop 5-HT3A serotonin receptor (5HT3R) reconstituted into saposin-based lipid bilayer discs: a symmetric and an asymmetric apo state, and an asymmetric agonist-bound state.	Cysteine	34-37	5-hydroxytryptamine receptor 3A	Homo sapiens	70-75
33594077-3	2021	We report three structures of the Cys-loop 5-HT3A serotonin receptor (5HT3R) reconstituted into saposin-based lipid bilayer discs: a symmetric and an asymmetric apo state, and an asymmetric agonist-bound state.	Lipid Bilayers	110-123	5-hydroxytryptamine receptor 3A	Homo sapiens	43-68
33594077-3	2021	We report three structures of the Cys-loop 5-HT3A serotonin receptor (5HT3R) reconstituted into saposin-based lipid bilayer discs: a symmetric and an asymmetric apo state, and an asymmetric agonist-bound state.	Lipid Bilayers	110-123	5-hydroxytryptamine receptor 3A	Homo sapiens	70-75
33419241-6	2020	Palonosetron, a serotonin type 3 receptor (5-hydroxytryptamine receptor 3 (5-HT3R)) antagonist, was identified by both CLUE and FAERS analyses.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	75-81
33555084-3	2021	Here, we analyze the use of NK1 RA-5-HT3 RA-dexamethasone for antiemetic prophylaxis associated with HEC and carboplatin.	HEC	101-104	5-hydroxytryptamine receptor 3A	Homo sapiens	35-40
33555084-3	2021	Here, we analyze the use of NK1 RA-5-HT3 RA-dexamethasone for antiemetic prophylaxis associated with HEC and carboplatin.	Carboplatin	109-120	5-hydroxytryptamine receptor 3A	Homo sapiens	35-40
33572981-3	2021	A member of a novel class of antidepressants, vortioxetine, which is a serotonin partial agonist reuptake inhibitor (SPARI), also exhibits a higher affinity for serotonin transporter, serotonin receptors type 1A (5-HT1AR) and type 3 (5-HT3R), and 5-HT7R.	Vortioxetine	46-58	5-hydroxytryptamine receptor 3A	Homo sapiens	234-240
33572981-3	2021	A member of a novel class of antidepressants, vortioxetine, which is a serotonin partial agonist reuptake inhibitor (SPARI), also exhibits a higher affinity for serotonin transporter, serotonin receptors type 1A (5-HT1AR) and type 3 (5-HT3R), and 5-HT7R.	Serotonin	161-170	5-hydroxytryptamine receptor 3A	Homo sapiens	234-240
33252737-1	2021	5-hydroxytryptamine receptor subtype 3 (5-HT3R) is a pentameric ligand-gated ion channel (pLGIC) involved in neuronal signaling.	Serotonin	0-19	5-hydroxytryptamine receptor 3A	Homo sapiens	40-46
32736413-4	2020	HTR3A is the main subunit of 5-hydroxytryptamine 3 (5-HT3) receptors, which are the only ligand-gated ion channels in 7 families of 5-HT receptors.	Serotonin	29-48	5-hydroxytryptamine receptor 3A	Homo sapiens	0-5
33059577-7	2021	The serotonin type-3 receptors (5-HT3R) are well renowned to be expressed in the central nervous system (CNS) in regions which have significance in the vomiting reflex, perception of pain, the reward system, cognition, depression and anxiety control.	Serotonin	4-13	5-hydroxytryptamine receptor 3A	Homo sapiens	32-38
33059577-9	2021	The 5-HT3RA inhibit the binding of serotonin to post synaptic 5-HT3R and increase its availability to other receptors like 5-HT1A, 1B and 1D as well as 5-HT2 receptors and produces anti-depressant-like effect.	Serotonin	35-44	5-hydroxytryptamine receptor 3A	Homo sapiens	4-10
32946769-9	2020	Thus, our kinetic analysis revealed that terpenoids are efficacious agonists for 5-HT3A receptors.	Terpenes	41-51	5-hydroxytryptamine receptor 3A	Homo sapiens	81-87
32736413-4	2020	HTR3A is the main subunit of 5-hydroxytryptamine 3 (5-HT3) receptors, which are the only ligand-gated ion channels in 7 families of 5-HT receptors.	Serotonin	52-56	5-hydroxytryptamine receptor 3A	Homo sapiens	0-5
32336093-2	2020	Using a simplified model of the pore of the 5HT3 receptor (5HT3R) which restrains the backbone structure to that of the parent channel protein from which it is derived we compare additive with polarizable models in describing the behavior of water in nanopores.	Water	242-247	5-hydroxytryptamine receptor 3A	Homo sapiens	44-57
32899016-2	2020	The Bezold-Jarisch reflex, causing postspinal hypotension, has been shown to be antagonized by serotonin type 3 (5-HT3) blockade.	Serotonin	95-104	5-hydroxytryptamine receptor 3A	Homo sapiens	113-118
32899016-3	2020	Our aim was to assess if routine prophylactic administration of the 5-HT3 antagonist ondansetron (ODS) attenuates postspinal change in maternal blood pressure.Elective CS under SpA were retrospectively analyzed.	Ondansetron	85-96	5-hydroxytryptamine receptor 3A	Homo sapiens	68-73
32479847-2	2020	In addition to its potent antioxidant effects, agmatine is an endogenous neuromodulator and has wide spectrum molecular actions on different receptor subtypes (NMDA, Imidazoline 1-2, alpha-2 adrenoreceptor, 5-HT2a, 5-HT3) and cellular signaling pathways (MAPK, PKA, NO, BDNF).	Agmatine	47-55	5-hydroxytryptamine receptor 3A	Homo sapiens	215-220
33315977-2	2020	Several studies have also shown that changes in serotonin receptors, especially 5HTR2A and 5HTR3A, can play an important role in incidence of cancers.	Serotonin	48-57	5-hydroxytryptamine receptor 3A	Homo sapiens	92-97
33315977-11	2020	Conclusion: The results indicated an increase in the mRNA expression of serotonin receptors (5HTR2A and 5HTR3A) in the tumor tissue compared to the marginal zone, which due to the mitogenic nature of these receptors, is likely to induce more proliferation of cancer cells.	Serotonin	72-81	5-hydroxytryptamine receptor 3A	Homo sapiens	105-110
32130678-7	2020	Luciferase reporter assay and biotin-avidin pull-down assay showed miR-1256 can directly target 5-hydroxytryptamine receptor 3A (HTR3A) in PTC cells.	Biotin	30-36	5-hydroxytryptamine receptor 3A	Homo sapiens	96-127
32130678-7	2020	Luciferase reporter assay and biotin-avidin pull-down assay showed miR-1256 can directly target 5-hydroxytryptamine receptor 3A (HTR3A) in PTC cells.	Biotin	30-36	5-hydroxytryptamine receptor 3A	Homo sapiens	129-134
32336093-2	2020	Using a simplified model of the pore of the 5HT3 receptor (5HT3R) which restrains the backbone structure to that of the parent channel protein from which it is derived we compare additive with polarizable models in describing the behavior of water in nanopores.	Water	242-247	5-hydroxytryptamine receptor 3A	Homo sapiens	59-64
32250181-1	2020	Ondansetron HCl is a (5-HT3) serotonin receptor antagonist, used as anti-emetic drug in combination with anticancer agents.	Ondansetron	0-15	5-hydroxytryptamine receptor 3A	Homo sapiens	22-47
32431598-5	2020	Also, macromolecular docking followed by 100 ns molecular dynamics (MD) simulations suggested that the interaction energy of the P2X4 receptor with 5-HT3A receptor is similar at the holo and the apo state of the P2X4 receptor, and the interacting 5-HT3A receptor decreased the ATP binding energy of P2X4 receptor.	Adenosine Triphosphate	277-280	5-hydroxytryptamine receptor 3A	Homo sapiens	148-154
32390801-4	2020	Methods: A set of 29 SNPs of genes of serotonin receptors HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR3B, and HTR6 was studied in a population of 449 Caucasians (226 females and 223 males) with verified clinical diagnosis of schizophrenia (according to ICD-10: F20).	Serotonin	38-47	5-hydroxytryptamine receptor 3A	Homo sapiens	86-91
31868947-3	2020	Several studies have related polymorphisms (SNPs) in the serotonin receptor-3 (HTR3) genes to be associated with pain modulation and endogenous pain suppression.	Serotonin	57-66	5-hydroxytryptamine receptor 3A	Homo sapiens	79-83
31868947-5	2020	Here, we investigated the effect of a 5"UTR SNP in the serotonergic receptor HTR3A gene (rs1062613) on striatal dopamine D2/D3 receptor (DRD2) availability and reward-associated DA release in response to unpredictable monetary rewards in 23 women with FMS and 17 age-matched healthy female controls.	Dopamine	178-180	5-hydroxytryptamine receptor 3A	Homo sapiens	77-82
31835640-1	2019	Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans.	Vortioxetine	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	146-151
31873866-3	2020	The 5-hydroxytryptamine (5-HT) receptor 3 antagonist alosetron is approved for women only since it largely lacks efficacy in men.	alosetron	53-62	5-hydroxytryptamine receptor 3A	Homo sapiens	4-41
31871207-0	2020	Microsecond-timescale simulations suggest 5-HT-mediated preactivation of the 5-HT3A serotonin receptor.	Serotonin	42-46	5-hydroxytryptamine receptor 3A	Homo sapiens	77-83
31871207-0	2020	Microsecond-timescale simulations suggest 5-HT-mediated preactivation of the 5-HT3A serotonin receptor.	Serotonin	84-93	5-hydroxytryptamine receptor 3A	Homo sapiens	77-83
31871207-3	2020	Here, we perform multiple all-atom MD simulations of the homomeric 5-hydroxytryptamine 3A (5-HT3A) serotonin receptor for 15 to 20 mus to demonstrate that such timescales are critical to observe the equilibration of a pLGIC from its crystalized conformation to a membrane-bound conformation.	Serotonin	67-86	5-hydroxytryptamine receptor 3A	Homo sapiens	91-97
31871207-3	2020	Here, we perform multiple all-atom MD simulations of the homomeric 5-hydroxytryptamine 3A (5-HT3A) serotonin receptor for 15 to 20 mus to demonstrate that such timescales are critical to observe the equilibration of a pLGIC from its crystalized conformation to a membrane-bound conformation.	Serotonin	99-108	5-hydroxytryptamine receptor 3A	Homo sapiens	91-97
31871207-4	2020	These timescales, which are an order of magnitude longer than any previous simulation of 5-HT3A, allow us to observe the dynamic binding and unbinding of 5-hydroxytryptamine (5-HT) (i.e., serotonin) to the binding pocket located on the extracellular domain (ECD) and allosteric regulation of the transmembrane domain (TMD) from synergistic 5-HT binding.	Serotonin	154-173	5-hydroxytryptamine receptor 3A	Homo sapiens	89-95
31871207-4	2020	These timescales, which are an order of magnitude longer than any previous simulation of 5-HT3A, allow us to observe the dynamic binding and unbinding of 5-hydroxytryptamine (5-HT) (i.e., serotonin) to the binding pocket located on the extracellular domain (ECD) and allosteric regulation of the transmembrane domain (TMD) from synergistic 5-HT binding.	Serotonin	188-197	5-hydroxytryptamine receptor 3A	Homo sapiens	89-95
31871207-4	2020	These timescales, which are an order of magnitude longer than any previous simulation of 5-HT3A, allow us to observe the dynamic binding and unbinding of 5-hydroxytryptamine (5-HT) (i.e., serotonin) to the binding pocket located on the extracellular domain (ECD) and allosteric regulation of the transmembrane domain (TMD) from synergistic 5-HT binding.	Serotonin	175-179	5-hydroxytryptamine receptor 3A	Homo sapiens	89-95
32616964-0	2020	X-Ray Crystal Structure of a 2-Amino-3,4-dihydroquinazoline 5-HT3 Serotonin Receptor Antagonist and Related Analogs.	1,4-dihydroquinazolin-2-amine	29-59	5-hydroxytryptamine receptor 3A	Homo sapiens	60-84
31835640-1	2019	Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans.	Vortioxetine	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	153-159
31582575-5	2019	In the present study, we used voltage-clamp fluorometry (VCF) to measure conformational changes in regions surrounding the orthosteric binding site of the human 5-HT3A (h5-HT3A) receptor during binding of 5-HT and different classes of 5-HT3 receptor ligands.	Serotonin	161-165	5-hydroxytryptamine receptor 3A	Homo sapiens	170-176
30992726-5	2019	In the presented work, we summarize the synthesis, photochromic properties and in vitro characterization of azobenzene-based photochromic derivatives of published 5-HT3R antagonists.	azobenzene	108-118	5-hydroxytryptamine receptor 3A	Homo sapiens	163-169
31409663-0	2019	Triple arginines as molecular determinants for pentameric assembly of the intracellular domain of 5-HT3A receptors.	Arginine	7-16	5-hydroxytryptamine receptor 3A	Homo sapiens	98-104
30797147-0	2019	Potential roles of 5-HT3 receptor (5-HT3R) antagonists in modulating the effects of nicotine.	Nicotine	84-92	5-hydroxytryptamine receptor 3A	Homo sapiens	19-33
30797147-0	2019	Potential roles of 5-HT3 receptor (5-HT3R) antagonists in modulating the effects of nicotine.	Nicotine	84-92	5-hydroxytryptamine receptor 3A	Homo sapiens	35-41
30797147-1	2019	5-HT3R antagonists such as ondansetron, granisetron and tropisetron have been clinically used to treat nausea and vomiting in chemotherapy patients.	Ondansetron	27-38	5-hydroxytryptamine receptor 3A	Homo sapiens	0-6
30797147-1	2019	5-HT3R antagonists such as ondansetron, granisetron and tropisetron have been clinically used to treat nausea and vomiting in chemotherapy patients.	Granisetron	40-51	5-hydroxytryptamine receptor 3A	Homo sapiens	0-6
30797147-1	2019	5-HT3R antagonists such as ondansetron, granisetron and tropisetron have been clinically used to treat nausea and vomiting in chemotherapy patients.	Tropisetron	56-67	5-hydroxytryptamine receptor 3A	Homo sapiens	0-6
30797147-5	2019	This review gathered existing studies conducted investigating the potential of "-setron" class of 5-HT3R antagonists in modulating nicotine effects.	Nicotine	131-139	5-hydroxytryptamine receptor 3A	Homo sapiens	98-104
30797147-6	2019	We proposed that the mechanism where 5-HT3R antagonists mediate the effects of nicotine could be attributed by both direct at 5-HT3R and indirect mechanism in nicotine addiction downstream regulation.	Nicotine	79-87	5-hydroxytryptamine receptor 3A	Homo sapiens	37-43
30797147-6	2019	We proposed that the mechanism where 5-HT3R antagonists mediate the effects of nicotine could be attributed by both direct at 5-HT3R and indirect mechanism in nicotine addiction downstream regulation.	Nicotine	79-87	5-hydroxytryptamine receptor 3A	Homo sapiens	126-132
30797147-6	2019	We proposed that the mechanism where 5-HT3R antagonists mediate the effects of nicotine could be attributed by both direct at 5-HT3R and indirect mechanism in nicotine addiction downstream regulation.	Nicotine	159-167	5-hydroxytryptamine receptor 3A	Homo sapiens	37-43
28869563-8	2017	The representative putative targets of the alkaloids are inflammation-related proteins (MAPK14, PTGS2, PTGS2, and F2) and pruritus-related proteins (HRH1, TRPA1, HTR3A, and HTR6).	Alkaloids	43-52	5-hydroxytryptamine receptor 3A	Homo sapiens	162-167
30317998-1	2019	BACKGROUND: Vortioxetine is a multimodal antidepressant drug with combined effects on SERT as an inhibitor, 5-HT1A as agonist and 5-HT3A as an antagonist.	Vortioxetine	12-24	5-hydroxytryptamine receptor 3A	Homo sapiens	130-136
30317998-2	2019	Series of vortioxetine analogs have been reported as multi antidepressant compounds and they block serotonin transport into the neuronal cells, activate the postsynaptic 5-HT1A receptors and eliminate the low activity of 5-HT3A receptors.	Vortioxetine	10-22	5-hydroxytryptamine receptor 3A	Homo sapiens	221-227
30405756-4	2018	HTR3A was then knocked down via a lentivirus-mediated shRNA system to detect the effect of HTR3A silencing on cell proliferation and apoptosis by MTT, colony formation, flow cytometry and western blotting assays in CRC.	monooxyethylene trimethylolpropane tristearate	146-149	5-hydroxytryptamine receptor 3A	Homo sapiens	91-96
29508995-5	2018	Examination of a range of receptor modulators, including ethanol, thymol, 5-hydroxyindole, and 5-chloroindole, which can affect the 5-HT3A receptor and ELIC, suggest that these compounds act via the transmembrane domain, except for 5-hydroxyindole, which can compete with 5-HT at the orthosteric binding site.	Ethanol	57-64	5-hydroxytryptamine receptor 3A	Homo sapiens	132-138
29508995-5	2018	Examination of a range of receptor modulators, including ethanol, thymol, 5-hydroxyindole, and 5-chloroindole, which can affect the 5-HT3A receptor and ELIC, suggest that these compounds act via the transmembrane domain, except for 5-hydroxyindole, which can compete with 5-HT at the orthosteric binding site.	Thymol	66-72	5-hydroxytryptamine receptor 3A	Homo sapiens	132-138
29508995-5	2018	Examination of a range of receptor modulators, including ethanol, thymol, 5-hydroxyindole, and 5-chloroindole, which can affect the 5-HT3A receptor and ELIC, suggest that these compounds act via the transmembrane domain, except for 5-hydroxyindole, which can compete with 5-HT at the orthosteric binding site.	5-hydroxyindole	74-89	5-hydroxytryptamine receptor 3A	Homo sapiens	132-138
29508995-5	2018	Examination of a range of receptor modulators, including ethanol, thymol, 5-hydroxyindole, and 5-chloroindole, which can affect the 5-HT3A receptor and ELIC, suggest that these compounds act via the transmembrane domain, except for 5-hydroxyindole, which can compete with 5-HT at the orthosteric binding site.	5-chloroindole	95-109	5-hydroxytryptamine receptor 3A	Homo sapiens	132-138
29508995-5	2018	Examination of a range of receptor modulators, including ethanol, thymol, 5-hydroxyindole, and 5-chloroindole, which can affect the 5-HT3A receptor and ELIC, suggest that these compounds act via the transmembrane domain, except for 5-hydroxyindole, which can compete with 5-HT at the orthosteric binding site.	5-hydroxyindole	232-247	5-hydroxytryptamine receptor 3A	Homo sapiens	132-138
29508995-6	2018	The data throw further light on the importance of coupling interface in Cys-loop receptors and provide a platform for examining the mechanism of action of compounds that act in the extracellular domain of the 5-HT3A receptor and the transmembrane domain of ELIC.	Cysteine	72-75	5-hydroxytryptamine receptor 3A	Homo sapiens	209-215
29620694-3	2018	The aim of this study was to determine whether genetic variations in the genes encoding muscarinic and serotonergic receptors (CHRM2, CHRM3, HTR2, HTR3, HTR4, and HTR7) explain the variations in incidence of constipation and anticholinergic symptoms during clozapine treatment.	Clozapine	257-266	5-hydroxytryptamine receptor 3A	Homo sapiens	147-151
29448118-9	2018	L-type calcium channel blocking antihypertensives (CCBs), were associated with a 3.18 mg/dL (95% CI -6.18 to -0.18) decrease in glucose during GTT, and serotonin receptor type 3 (5HT-3) antagonist antinausea medications were associated with a 3.54 mg/dL (95% CI 1.86-5.23) increase in glucose during GTT.	ccbs	51-55	5-hydroxytryptamine receptor 3A	Homo sapiens	152-184
30257860-0	2018	Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT3A Receptor.	Vortioxetine	92-104	5-hydroxytryptamine receptor 3A	Homo sapiens	118-124
30257860-6	2018	We have investigated the binding mode of vortioxetine at the human 5-HT3A receptor through computational and in vitro experiments to provide insight into the molecular mechanisms behind the unique pharmacological profile of the drug.	Vortioxetine	41-53	5-hydroxytryptamine receptor 3A	Homo sapiens	67-73
29972203-7	2018	The CML-induced serotonin release was reduced by the HTR3 antagonist granisetron.	Serotonin	16-25	5-hydroxytryptamine receptor 3A	Homo sapiens	53-57
29972203-7	2018	The CML-induced serotonin release was reduced by the HTR3 antagonist granisetron.	Granisetron	69-80	5-hydroxytryptamine receptor 3A	Homo sapiens	53-57
28439104-3	2018	In this study, we show that a serotonin type 3 receptor (5HT3R) agonist induces antidepressant effects as well as hippocampal neurogenesis independent of fluoxetine (a commonly used SSRI).	Fluoxetine	154-164	5-hydroxytryptamine receptor 3A	Homo sapiens	30-62
28615161-10	2017	Decreasing the glucose concentration also decreased both basal and 5-HT3R agonist-induced increase in the frequency of spontaneous glutamate inputs onto NTS-CA neurons.	Glucose	15-22	5-hydroxytryptamine receptor 3A	Homo sapiens	67-73
28615161-10	2017	Decreasing the glucose concentration also decreased both basal and 5-HT3R agonist-induced increase in the frequency of spontaneous glutamate inputs onto NTS-CA neurons.	Glutamic Acid	131-140	5-hydroxytryptamine receptor 3A	Homo sapiens	67-73
28948091-0	2017	Successful treatment with risperidone increases 5-HT 3A receptor gene expression in patients with paranoid schizophrenia - data from a prospective study.	Risperidone	26-37	5-hydroxytryptamine receptor 3A	Homo sapiens	48-55
28948091-1	2017	INTRODUCTION: The relationship between peripheral 5-HT3A receptor mRNA level and risperidone efficiency in paranoid schizophrenia patients is still unknown.	Risperidone	81-92	5-hydroxytryptamine receptor 3A	Homo sapiens	50-56
28948091-9	2017	CONCLUSIONS: Successful treatment with risperidone increases 5-HT3A receptor gene expression in patients with paranoid schizophrenia, indicating that 5-HT3A receptor may be involved in the mechanism of risperidone effect.	Risperidone	39-50	5-hydroxytryptamine receptor 3A	Homo sapiens	61-67
28948091-9	2017	CONCLUSIONS: Successful treatment with risperidone increases 5-HT3A receptor gene expression in patients with paranoid schizophrenia, indicating that 5-HT3A receptor may be involved in the mechanism of risperidone effect.	Risperidone	39-50	5-hydroxytryptamine receptor 3A	Homo sapiens	150-156
28948091-9	2017	CONCLUSIONS: Successful treatment with risperidone increases 5-HT3A receptor gene expression in patients with paranoid schizophrenia, indicating that 5-HT3A receptor may be involved in the mechanism of risperidone effect.	Risperidone	202-213	5-hydroxytryptamine receptor 3A	Homo sapiens	61-67
28948091-9	2017	CONCLUSIONS: Successful treatment with risperidone increases 5-HT3A receptor gene expression in patients with paranoid schizophrenia, indicating that 5-HT3A receptor may be involved in the mechanism of risperidone effect.	Risperidone	202-213	5-hydroxytryptamine receptor 3A	Homo sapiens	150-156
27874067-7	2016	Moreover, activation of 5-HTR3 and 5-HTR4 both significantly inhibited the opening of mPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	86-90	5-hydroxytryptamine receptor 3A	Homo sapiens	26-30
28606760-1	2017	The vertebrate Cys-loop family of ligand-gated ion channels (LGICs) are comprised of nicotinic acetylcholine (nAChR), serotonin type 3 (5-HT3R), gamma-aminobutyric acid (GABAAR), and glycine (GlyR) receptors.	Cysteine	15-18	5-hydroxytryptamine receptor 3A	Homo sapiens	118-142
27926574-4	2017	Serotonin in mammal species has multiple neural markers, including receptors (5-HT1-7), serotonin transporter, and volume transmission, which are present in brain areas involved in memory.	Serotonin	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	78-85
27816366-3	2017	5-Hydroxytryptamine receptor 3 (5-HT3) antagonists like ondansetron and ramosetron are commonly used for preventing PONV, but the optimal choice remains unclear.	Ondansetron	56-67	5-hydroxytryptamine receptor 3A	Homo sapiens	0-30
27816366-3	2017	5-Hydroxytryptamine receptor 3 (5-HT3) antagonists like ondansetron and ramosetron are commonly used for preventing PONV, but the optimal choice remains unclear.	ramosetron	72-82	5-hydroxytryptamine receptor 3A	Homo sapiens	0-30
27866853-4	2016	Using the serotonin receptor (5-HT3R) structure as an example, we demonstrate the use of molecular dynamics to aid the functional annotation of channel structures via simulation of the behavior of water within the pore.	Water	197-202	5-hydroxytryptamine receptor 3A	Homo sapiens	30-36
28002447-9	2016	Women carrying the C/T & T/T (HTR3A) genotype had less reduction of pain intensity (P = 0.041) and area (P = 0.005), and women with the C/C genotype (HTR3B) had less reduction of pain intensity (P = 0.030), duration (P = 0.030) and area compared to men (P = 0.017).	Adenosine Monophosphate	24-27	5-hydroxytryptamine receptor 3A	Homo sapiens	34-39
27870735-9	2016	CONCLUSION: Combination of a 5-HT3 receptor antagonist and dexamethasone is significantly more effective than 5-HT3 antagonist alone in preventing PONV after laparoscopic surgeries, with possible improvement in postoperative analgesia.	Dexamethasone	59-72	5-hydroxytryptamine receptor 3A	Homo sapiens	110-115
27677804-0	2016	Novel mechanism of modulation at a ligand-gated ion channel; action of 5-Cl-indole at the 5-HT3 A receptor.	5-cl-indole	71-82	5-hydroxytryptamine receptor 3A	Homo sapiens	90-97
27677804-3	2016	We have investigated the pharmacological action of Cl-indole upon the 5-HT3 A receptor and identified that this positive allosteric modulator possesses a novel mechanism of action for LGICs.	cl-indole	51-60	5-hydroxytryptamine receptor 3A	Homo sapiens	70-77
27677804-6	2016	However, in the presence of Cl-indole, termination of 5-HT application revealed tail currents mediated via the 5-HT3 A receptor that were independent of the preceding 5-HT concentration but were antagonized by the 5-HT3 receptor antagonist, ondansetron.	cl-indole	28-37	5-hydroxytryptamine receptor 3A	Homo sapiens	111-118
27677804-6	2016	However, in the presence of Cl-indole, termination of 5-HT application revealed tail currents mediated via the 5-HT3 A receptor that were independent of the preceding 5-HT concentration but were antagonized by the 5-HT3 receptor antagonist, ondansetron.	Ondansetron	241-252	5-hydroxytryptamine receptor 3A	Homo sapiens	111-118
27677804-8	2016	Furthermore, the presence of 5-HT revealed a concentration-dependent increase in the affinity of Cl-indole for the orthosteric binding site of the human 5-HT3 A receptor.	cl-indole	97-106	5-hydroxytryptamine receptor 3A	Homo sapiens	153-160
27144979-0	2016	The association of HTR3A mRNA expression and craving in Han Chinese alcohol-dependent patients: a preliminary study.	Alcohols	68-75	5-hydroxytryptamine receptor 3A	Homo sapiens	19-24
27144979-8	2016	RESULTS: HTR3A mRNA expression levels and acetylation levels of H3K9 in the HTR3A promoter region were significantly higher in the alcohol-dependent patients.	Alcohols	131-138	5-hydroxytryptamine receptor 3A	Homo sapiens	9-14
27144979-8	2016	RESULTS: HTR3A mRNA expression levels and acetylation levels of H3K9 in the HTR3A promoter region were significantly higher in the alcohol-dependent patients.	Alcohols	131-138	5-hydroxytryptamine receptor 3A	Homo sapiens	76-81
27144979-11	2016	CONCLUSION: The current findings suggest that HTR3A mRNA expression levels were positively correlated with craving in Han Chinese alcohol-dependent patients.	Alcohols	130-137	5-hydroxytryptamine receptor 3A	Homo sapiens	46-51
26869399-5	2016	Our results indicate that DPA is an allosteric modulator of GABArho1 receptors with an IC50 of 1.6 microM, an enhancer of alpha7 nicotinic receptors at relatively high concentrations of DPA, and has little, if any, effect on 5-HT3A receptors.	dipicrylamine	26-29	5-hydroxytryptamine receptor 3A	Homo sapiens	225-231
27050932-4	2016	Vortioxetine (VRX) is a multimodal antidepressant with a unique mechanism of action, by acting as 5-HT3A, 5-HT1D and 5-HT7 receptor antagonist, partial agonist at the 5-HT1A and 5-HT1B receptors and inhibitor at the 5-HT transporter.	Vortioxetine	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	98-104
27050932-4	2016	Vortioxetine (VRX) is a multimodal antidepressant with a unique mechanism of action, by acting as 5-HT3A, 5-HT1D and 5-HT7 receptor antagonist, partial agonist at the 5-HT1A and 5-HT1B receptors and inhibitor at the 5-HT transporter.	Vortioxetine	14-17	5-hydroxytryptamine receptor 3A	Homo sapiens	98-104
27044837-3	2016	In brain, Zn(2+) has been identified as a ligand, capable of activating and inhibiting the receptors including the NMDA-type glutamate receptors (NMDARs), GABAA receptors, nicotinic acetylcholine receptors (nAChRs), glycine receptors (glyR) and serotonin receptors (5-HT3).	Zinc	10-12	5-hydroxytryptamine receptor 3A	Homo sapiens	266-272
26869399-8	2016	In silico modeling of DPA docking to GABArho1, alpha7 nicotinic, and 5-HT3A receptors suggests that a hydrophobic pocket within the Cys-loop and the M4 segment in GABArho1, located at the extracellular/membrane interface, facilitates the interaction with DPA that leads to inhibition of the receptor.	dipicrylamine	22-25	5-hydroxytryptamine receptor 3A	Homo sapiens	69-75
26869399-8	2016	In silico modeling of DPA docking to GABArho1, alpha7 nicotinic, and 5-HT3A receptors suggests that a hydrophobic pocket within the Cys-loop and the M4 segment in GABArho1, located at the extracellular/membrane interface, facilitates the interaction with DPA that leads to inhibition of the receptor.	Cysteine	132-135	5-hydroxytryptamine receptor 3A	Homo sapiens	69-75
26456648-5	2015	Whereas the action of all of these substances is well described, less is known about the effect of terpenoids or fragrances on 5-HT3A receptors.	Terpenes	99-109	5-hydroxytryptamine receptor 3A	Homo sapiens	127-133
26701104-0	2015	Influence of the 5-HT3A Receptor Gene Polymorphism and Childhood Sexual Trauma on Central Serotonin Activity.	Serotonin	90-99	5-hydroxytryptamine receptor 3A	Homo sapiens	17-23
26576669-10	2016	Selective 5-HT3R antagonists (ondansetron, tropisetron and granisetron) showed positive results on negative symptoms and/or cognitive impairments in phase II trials.	Ondansetron	30-41	5-hydroxytryptamine receptor 3A	Homo sapiens	10-16
26576669-10	2016	Selective 5-HT3R antagonists (ondansetron, tropisetron and granisetron) showed positive results on negative symptoms and/or cognitive impairments in phase II trials.	Tropisetron	43-54	5-hydroxytryptamine receptor 3A	Homo sapiens	10-16
26576669-10	2016	Selective 5-HT3R antagonists (ondansetron, tropisetron and granisetron) showed positive results on negative symptoms and/or cognitive impairments in phase II trials.	Granisetron	59-70	5-hydroxytryptamine receptor 3A	Homo sapiens	10-16
26456648-8	2015	A screening of two odorous mixes containing a total of 200 substances revealed that the monoterpenes, thymol and carvacrol, act as both weak partial agonists and positive modulators on the 5-HT3A receptor.	Monoterpenes	88-100	5-hydroxytryptamine receptor 3A	Homo sapiens	189-195
26456648-8	2015	A screening of two odorous mixes containing a total of 200 substances revealed that the monoterpenes, thymol and carvacrol, act as both weak partial agonists and positive modulators on the 5-HT3A receptor.	Thymol	102-108	5-hydroxytryptamine receptor 3A	Homo sapiens	189-195
26456648-8	2015	A screening of two odorous mixes containing a total of 200 substances revealed that the monoterpenes, thymol and carvacrol, act as both weak partial agonists and positive modulators on the 5-HT3A receptor.	carvacrol	113-122	5-hydroxytryptamine receptor 3A	Homo sapiens	189-195
26456648-10	2015	In our study, we identified new modulators of 5-HT3A receptors out of the classes of monoterpenes and vanilloid substances that frequently occur in various plants.	Monoterpenes	85-97	5-hydroxytryptamine receptor 3A	Homo sapiens	46-52
26456648-10	2015	In our study, we identified new modulators of 5-HT3A receptors out of the classes of monoterpenes and vanilloid substances that frequently occur in various plants.	Capsaicin	102-111	5-hydroxytryptamine receptor 3A	Homo sapiens	46-52
25277140-3	2014	Here we examine the effects of proguanil and its metabolites on the electrophysiology and ligand-binding properties of human 5-HT3A receptors expressed in Xenopus oocytes and human embryonic kidney 293 cells, respectively.	Proguanil	31-40	5-hydroxytryptamine receptor 3A	Homo sapiens	125-131
26073329-2	2015	METHODS: Codon-optimized cDNA of human 5-HT3A was inserted into a modified BacMam vector, which contained an IgG leader sequence, an 8xHis tag linked with two-Maltose Binding Proteins (MBP), and a TEV protease cleavage site.	Maltose	159-166	5-hydroxytryptamine receptor 3A	Homo sapiens	39-45
26073329-3	2015	The BacMam construct was used to generate baculoviruses for expression of 5-HT3A in HEK293F cells.	bacmam	4-10	5-hydroxytryptamine receptor 3A	Homo sapiens	74-80
26073329-9	2015	RESULTS: The BacMam system yielded 0.5 milligram of the human 5-HT3A receptor per liter of cells.	bacmam	13-19	5-hydroxytryptamine receptor 3A	Homo sapiens	62-68
25948478-7	2015	Br-IQ17B is selective over other subtypes such as alpha4beta2 and alpha3beta4, but it blocks 5-HT3A receptors.	br-iq17b	0-8	5-hydroxytryptamine receptor 3A	Homo sapiens	93-99
25863270-0	2015	Fast and slow interactions of n-alkanols with human 5-HT3A receptors: Implications for anesthetic mechanisms.	n-alkanols	30-40	5-hydroxytryptamine receptor 3A	Homo sapiens	52-58
25428414-2	2015	To identify biomarkers predicting effectiveness of the 5-HT3 R antagonist (ramosetron) in IBS-D. METHODS: Irritable bowel syndrome-D Japanese subjects received 2.5 or 5 mug of ramosetron once daily for 4 weeks.	ramosetron	75-85	5-hydroxytryptamine receptor 3A	Homo sapiens	55-62
26565961-5	2015	Facilitation of pain behaviour induced by GAL in the DMH was reversed by lidocaine in the DRt and by ondansetron, a 5HT3R antagonist, in the spinal cord.	Dimenhydrinate	53-56	5-hydroxytryptamine receptor 3A	Homo sapiens	116-121
26565961-5	2015	Facilitation of pain behaviour induced by GAL in the DMH was reversed by lidocaine in the DRt and by ondansetron, a 5HT3R antagonist, in the spinal cord.	Ondansetron	101-112	5-hydroxytryptamine receptor 3A	Homo sapiens	116-121
25485645-0	2015	The effects of varenicline on sensory gating and exploratory behavior with pretreatment with nicotinic or 5-HT3A receptor antagonists.	Varenicline	15-26	5-hydroxytryptamine receptor 3A	Homo sapiens	106-112
25485645-3	2015	Varenicline, a nonselective neuronal nicotinic receptor (NNR) agonist and full agonist of 5-HT3A receptors, helps reduce smoking among schizophrenic patients.	Varenicline	0-11	5-hydroxytryptamine receptor 3A	Homo sapiens	90-96
25485645-8	2015	Collectively, these results indicate that varenicline at low-to-moderate doses may be beneficial against impaired sensory gating in schizophrenia; however, higher doses may induce anxiogenic effects, which can be prevented with antagonists of NNRs or 5-HT3A receptors.	Varenicline	42-53	5-hydroxytryptamine receptor 3A	Homo sapiens	251-257
25409778-2	2014	Here we show that the ionotropic serotonin receptor 3A (5-HT(3A)R) is specifically expressed in CGE-derived migrating interneurons and upregulated while they invade the developing cortex.	Clopidogrel	96-99	5-hydroxytryptamine receptor 3A	Homo sapiens	33-54
25409778-2	2014	Here we show that the ionotropic serotonin receptor 3A (5-HT(3A)R) is specifically expressed in CGE-derived migrating interneurons and upregulated while they invade the developing cortex.	Clopidogrel	96-99	5-hydroxytryptamine receptor 3A	Homo sapiens	56-63
22458709-1	2014	5-hydroxytryptamine 3 (5HT3) receptors are important modulators of mesostriatal dopaminergic transmission and have been implicated in the pathophysiology of cocaine reward, withdrawal and self-administration.	Cocaine	157-164	5-hydroxytryptamine receptor 3A	Homo sapiens	23-27
24590579-0	2014	Direct effects of morphine but not of fentanyl-type opioids on human 5-HT3A receptors in outside-out patch-clamp studies.	Morphine	18-26	5-hydroxytryptamine receptor 3A	Homo sapiens	69-75
24590579-4	2014	Therefore, this study focuses on the interaction of morphine and fentanyl-type opioids (alfentanil, remifentanil and sufentanil) with 5-HT3A receptors.	Morphine	52-60	5-hydroxytryptamine receptor 3A	Homo sapiens	134-140
24590579-4	2014	Therefore, this study focuses on the interaction of morphine and fentanyl-type opioids (alfentanil, remifentanil and sufentanil) with 5-HT3A receptors.	Fentanyl	65-73	5-hydroxytryptamine receptor 3A	Homo sapiens	134-140
24590579-4	2014	Therefore, this study focuses on the interaction of morphine and fentanyl-type opioids (alfentanil, remifentanil and sufentanil) with 5-HT3A receptors.	Alfentanil	88-98	5-hydroxytryptamine receptor 3A	Homo sapiens	134-140
24590579-4	2014	Therefore, this study focuses on the interaction of morphine and fentanyl-type opioids (alfentanil, remifentanil and sufentanil) with 5-HT3A receptors.	Remifentanil	100-112	5-hydroxytryptamine receptor 3A	Homo sapiens	134-140
24590579-4	2014	Therefore, this study focuses on the interaction of morphine and fentanyl-type opioids (alfentanil, remifentanil and sufentanil) with 5-HT3A receptors.	Sufentanil	117-127	5-hydroxytryptamine receptor 3A	Homo sapiens	134-140
24590579-11	2014	CONCLUSIONS: Morphine is an opioid compound exhibiting special antagonistic interaction with 5-HT3A receptors.	Morphine	13-21	5-hydroxytryptamine receptor 3A	Homo sapiens	93-99
25238823-5	2014	The expression of enzymes involved in 5HT synthesis and their receptors varied markedly in beta-pancreatic cells during pregnancy, in parallel with an increase in their insulin secretion potential (probably through the action of Htr3a) and an increase in beta-cell mass (through the action of Htr2b and Htr1d).	Serotonin	38-41	5-hydroxytryptamine receptor 3A	Homo sapiens	229-234
24283776-1	2014	BACKGROUND AND PURPOSE: It has been proposed that arginine residues lining the intracellular portals of the homomeric 5-HT3 A receptor cause electrostatic repulsion of cation flow, accounting for a single-channel conductance substantially lower than that of the 5-HT3 AB heteromer.	Arginine	50-58	5-hydroxytryptamine receptor 3A	Homo sapiens	118-125
24283776-3	2014	EXPERIMENTAL APPROACH: Mutations were introduced into the portal region of the human 5-HT3 A homopentamer, such that putative salt bridges were broken by neutralizing anionic partners.	Salts	126-130	5-hydroxytryptamine receptor 3A	Homo sapiens	85-92
22458709-2	2014	In addition, the 5HT3 antagonist ondansetron is effective in treating early-onset, but not late-onset, alcohol-dependent subjects.	Ondansetron	33-44	5-hydroxytryptamine receptor 3A	Homo sapiens	17-21
24128813-3	2013	To test this hypothesis we mutated a series of residues in the 5-HT3A receptor subunit (Tyr(73), Phe(130), Ser(163), and Asp(165)) and in the 5-HT3B receptor subunit (His(73), Phe(130), Glu(170), and Tyr(143)) that were previously predicted by in silico docking studies to interact with palonosetron.	Tyrosine	88-91	5-hydroxytryptamine receptor 3A	Homo sapiens	63-69
24388024-6	2014	Seventeen percent of patients given 5HT3R antagonists (n=242) and 22% of controls (n=220) had postoperative QTc exceeding 500 milliseconds.	qtc	108-111	5-hydroxytryptamine receptor 3A	Homo sapiens	36-41
24388024-10	2014	The QTc was prolonged, but not significantly, in diabetic patients given 5HT3R antagonists (P=.16).	qtc	4-7	5-hydroxytryptamine receptor 3A	Homo sapiens	73-78
24128813-7	2013	Overall, the data support a binding site for palonosetron at the classic orthosteric binding pocket between two 5-HT3A receptor subunits but not at allosteric sites previously identified by in silico modelling and docking.	Palonosetron	45-57	5-hydroxytryptamine receptor 3A	Homo sapiens	112-118
24030822-2	2013	Consistent with these models, two arginine residues (Arg(436) and Arg(440)) within the MA helix of 5-hydroxytryptamine type 3A (5-HT3A) receptors act singularly as rate-limiting determinants of single-channel conductance (gamma).	Arginine	34-42	5-hydroxytryptamine receptor 3A	Homo sapiens	128-134
23792067-4	2013	RESULTS: Phenol, pyrrole and alkyl amines, constituents of 5-HT, even at high concentrations, cannot activate 5-HT3A receptors but they can inhibit them.	Phenol	9-15	5-hydroxytryptamine receptor 3A	Homo sapiens	110-116
23792067-4	2013	RESULTS: Phenol, pyrrole and alkyl amines, constituents of 5-HT, even at high concentrations, cannot activate 5-HT3A receptors but they can inhibit them.	Pyrroles	17-24	5-hydroxytryptamine receptor 3A	Homo sapiens	110-116
23792067-4	2013	RESULTS: Phenol, pyrrole and alkyl amines, constituents of 5-HT, even at high concentrations, cannot activate 5-HT3A receptors but they can inhibit them.	alkyl amines	29-41	5-hydroxytryptamine receptor 3A	Homo sapiens	110-116
24030822-4	2013	We probed the majority of residues within the MA helix of the human 5-HT3A subunit using alanine- and arginine-scanning mutagenesis and the substituted cysteine accessibility method to determine their relative influences upon gamma.	Cysteine	152-160	5-hydroxytryptamine receptor 3A	Homo sapiens	68-74
24030822-2	2013	Consistent with these models, two arginine residues (Arg(436) and Arg(440)) within the MA helix of 5-hydroxytryptamine type 3A (5-HT3A) receptors act singularly as rate-limiting determinants of single-channel conductance (gamma).	Arginine	53-56	5-hydroxytryptamine receptor 3A	Homo sapiens	128-134
24030822-2	2013	Consistent with these models, two arginine residues (Arg(436) and Arg(440)) within the MA helix of 5-hydroxytryptamine type 3A (5-HT3A) receptors act singularly as rate-limiting determinants of single-channel conductance (gamma).	Arginine	66-69	5-hydroxytryptamine receptor 3A	Homo sapiens	128-134
24030822-2	2013	Consistent with these models, two arginine residues (Arg(436) and Arg(440)) within the MA helix of 5-hydroxytryptamine type 3A (5-HT3A) receptors act singularly as rate-limiting determinants of single-channel conductance (gamma).	Serotonin	99-118	5-hydroxytryptamine receptor 3A	Homo sapiens	128-134
24030822-4	2013	We probed the majority of residues within the MA helix of the human 5-HT3A subunit using alanine- and arginine-scanning mutagenesis and the substituted cysteine accessibility method to determine their relative influences upon gamma.	Alanine	89-96	5-hydroxytryptamine receptor 3A	Homo sapiens	68-74
24030822-4	2013	We probed the majority of residues within the MA helix of the human 5-HT3A subunit using alanine- and arginine-scanning mutagenesis and the substituted cysteine accessibility method to determine their relative influences upon gamma.	Arginine	102-110	5-hydroxytryptamine receptor 3A	Homo sapiens	68-74
23897038-2	2013	In this study, they explored additional markers of ondansetron treatment response in alcoholics by examining polymorphisms in the HTR3A and HTR3B genes, which regulate directly the function and binding of 5-HT3 receptors to ondansetron.	Ondansetron	51-62	5-hydroxytryptamine receptor 3A	Homo sapiens	130-135
23810831-7	2013	Replacement of the D loop amino acid triplet RQY of the 5-HT3A subunit, with the aligned residues from the 5-HT3B subunit, QEV, converts 5-HT to a weak partial agonist in both the homomer and heteromer, but does not compromise activation by mCPBG.	1-(3-chlorophenyl)biguanide	241-246	5-hydroxytryptamine receptor 3A	Homo sapiens	56-62
23897038-2	2013	In this study, they explored additional markers of ondansetron treatment response in alcoholics by examining polymorphisms in the HTR3A and HTR3B genes, which regulate directly the function and binding of 5-HT3 receptors to ondansetron.	Ondansetron	224-235	5-hydroxytryptamine receptor 3A	Homo sapiens	130-135
23897038-6	2013	RESULTS: Individuals carrying one or more of genotypes rs1150226-AG and rs1176713-GG in HTR3A and rs17614942-AC in HTR3B showed a significant overall mean difference between ondansetron and placebo in drinks per drinking day (22.50; effect size=0.867), percentage of heavy drinking days (220.58%; effect size=0.780), and percentage of days abstinent (18.18%; effect size=0.683).	Ondansetron	174-185	5-hydroxytryptamine receptor 3A	Homo sapiens	88-93
23822584-4	2013	KEY RESULTS: Dopamine, quipazine and VUF10166 were partial agonists at wild type 5-HT3A and 5-HT3AB receptors, with quipazine and VUF10166 causing a long-lived (>20 min) inhibition of subsequent agonist responses.	Dopamine	13-21	5-hydroxytryptamine receptor 3A	Homo sapiens	81-87
23822584-4	2013	KEY RESULTS: Dopamine, quipazine and VUF10166 were partial agonists at wild type 5-HT3A and 5-HT3AB receptors, with quipazine and VUF10166 causing a long-lived (>20 min) inhibition of subsequent agonist responses.	Quipazine	23-32	5-hydroxytryptamine receptor 3A	Homo sapiens	81-87
23822584-4	2013	KEY RESULTS: Dopamine, quipazine and VUF10166 were partial agonists at wild type 5-HT3A and 5-HT3AB receptors, with quipazine and VUF10166 causing a long-lived (>20 min) inhibition of subsequent agonist responses.	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	37-45	5-hydroxytryptamine receptor 3A	Homo sapiens	81-87
23822584-6	2013	A T6"S substitution in the 5-HT3A subunit decreased EC50 and increased Rmax of dopamine and quipazine at both homomeric and heteromeric receptors.	Dopamine	79-87	5-hydroxytryptamine receptor 3A	Homo sapiens	27-33
23822584-6	2013	A T6"S substitution in the 5-HT3A subunit decreased EC50 and increased Rmax of dopamine and quipazine at both homomeric and heteromeric receptors.	Quipazine	92-101	5-hydroxytryptamine receptor 3A	Homo sapiens	27-33
23822584-8	2013	CONCLUSIONS AND IMPLICATIONS: These results indicate that a mutation in the pore lining domain in both 5-HT3A and 5-HT3AB receptors alters the relative efficacy of a series of agonists, changing some (e.g. quipazine) from apparent antagonists to potent and efficacious agonists.	Quipazine	206-215	5-hydroxytryptamine receptor 3A	Homo sapiens	103-115
23305320-4	2013	Topotecan inhibited 5-HT-gated current through homomeric 5-HT3A receptors.	Topotecan	0-9	5-hydroxytryptamine receptor 3A	Homo sapiens	57-63
23640722-0	2013	Structure-activity relationships of quinoxaline-based 5-HT3A and 5-HT3AB receptor-selective ligands.	Quinoxalines	36-47	5-hydroxytryptamine receptor 3A	Homo sapiens	54-60
23640722-3	2013	During a recent fragment screen, 2-chloro-3-(4-methylpiperazin-1-yl)quinoxaline (VUF10166) was identified as a ligand that displays an 83-fold difference in [(3)H]granisetron binding affinity between 5-HT3A and 5-HT3AB receptors.	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	33-79	5-hydroxytryptamine receptor 3A	Homo sapiens	200-206
23640722-3	2013	During a recent fragment screen, 2-chloro-3-(4-methylpiperazin-1-yl)quinoxaline (VUF10166) was identified as a ligand that displays an 83-fold difference in [(3)H]granisetron binding affinity between 5-HT3A and 5-HT3AB receptors.	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	81-89	5-hydroxytryptamine receptor 3A	Homo sapiens	200-206
23640722-4	2013	Fragment hit exploration, initiated from VUF10166 and 3-(4-methylpiperazin-1-yl)quinoxalin-2-ol, resulted in a series of compounds with higher affinity at either 5-HT3A or 5-HT3AB receptors.	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	41-49	5-hydroxytryptamine receptor 3A	Homo sapiens	162-168
23640722-4	2013	Fragment hit exploration, initiated from VUF10166 and 3-(4-methylpiperazin-1-yl)quinoxalin-2-ol, resulted in a series of compounds with higher affinity at either 5-HT3A or 5-HT3AB receptors.	3-(4-methylpiperazin-1-yl)quinoxalin-2-ol	54-95	5-hydroxytryptamine receptor 3A	Homo sapiens	162-168
23640722-6	2013	At the extremes of the new compounds were 2-amino-3-(4-methylpiperazin-1-yl)quinoxaline, which showed 11-fold selectivity for the 5-HT3A receptor, and 2-(4-methylpiperazin-1-yl)quinoxaline, which showed an 8.3-fold selectivity for the 5-HT3AB receptor.	2-amino-3-(4-methylpiperazin-1-yl)quinoxaline	42-87	5-hydroxytryptamine receptor 3A	Homo sapiens	130-136
23594147-5	2013	KEY RESULTS: Cl-indole (1-100 muM) potentiated agonist (5-HT) and particularly partial agonist [(S)-zacopride, DDP733, RR210, quipazine, dopamine, 2-methyl-5-HT, SR57227A, meta chlorophenyl biguanide] induced h5-HT3A receptor-mediated responses.	5-chloroindole	13-22	5-hydroxytryptamine receptor 3A	Homo sapiens	210-216
23126479-4	2013	Furthermore, it has been reported that the 5-HTR3 antagonist ondansetron is efficacious in the treatment of Gilles de la Tourette syndrome (GTS).	Ondansetron	61-72	5-hydroxytryptamine receptor 3A	Homo sapiens	45-49
23290502-1	2013	BACKGROUND: Pharmacologic studies implicate a significant role of genes encoding the serotonin transporter (SLC6A4) and the 5-HT3AB subunits HTR3A and HTR3B in nicotine dependence (ND).	Nicotine	160-168	5-hydroxytryptamine receptor 3A	Homo sapiens	141-146
23321066-1	2013	Human serotonin receptor 3A (5-HT3A) is a ligand-gated ion channel regulated by serotonin.	Serotonin	6-15	5-hydroxytryptamine receptor 3A	Homo sapiens	29-35
23321066-4	2013	The purified P9-5-HT3A was efficiently reconstituted into proteoliposomes, and the serotonin-dependent ion-channel activity of P9-5-HT3A was observed by measuring the increased fluorescence of Fluo-3 attributed to the formation of a complex with the Ca(2+) ions released from the proteoliposomes.	Serotonin	83-92	5-hydroxytryptamine receptor 3A	Homo sapiens	16-22
23321066-4	2013	The purified P9-5-HT3A was efficiently reconstituted into proteoliposomes, and the serotonin-dependent ion-channel activity of P9-5-HT3A was observed by measuring the increased fluorescence of Fluo-3 attributed to the formation of a complex with the Ca(2+) ions released from the proteoliposomes.	Serotonin	83-92	5-hydroxytryptamine receptor 3A	Homo sapiens	130-136
23321066-4	2013	The purified P9-5-HT3A was efficiently reconstituted into proteoliposomes, and the serotonin-dependent ion-channel activity of P9-5-HT3A was observed by measuring the increased fluorescence of Fluo-3 attributed to the formation of a complex with the Ca(2+) ions released from the proteoliposomes.	Fluo-3	193-199	5-hydroxytryptamine receptor 3A	Homo sapiens	16-22
23321066-4	2013	The purified P9-5-HT3A was efficiently reconstituted into proteoliposomes, and the serotonin-dependent ion-channel activity of P9-5-HT3A was observed by measuring the increased fluorescence of Fluo-3 attributed to the formation of a complex with the Ca(2+) ions released from the proteoliposomes.	Fluo-3	193-199	5-hydroxytryptamine receptor 3A	Homo sapiens	130-136
23321066-5	2013	Alanine substitution for Trp178 of 5-HT3A abolished the serotonin-dependent ion-channel activity, confirming the importance of Trp178 as a ligand-binding site.	Alanine	0-7	5-hydroxytryptamine receptor 3A	Homo sapiens	35-41
23321066-5	2013	Alanine substitution for Trp178 of 5-HT3A abolished the serotonin-dependent ion-channel activity, confirming the importance of Trp178 as a ligand-binding site.	Serotonin	56-65	5-hydroxytryptamine receptor 3A	Homo sapiens	35-41
23321066-6	2013	Furthermore, the ion-channel activity of the reconstituted P9-5-HT3A was effectively blocked by treatment with ondansetron, an antagonist of 5-HT3A.	Ondansetron	111-122	5-hydroxytryptamine receptor 3A	Homo sapiens	62-68
23321066-6	2013	Furthermore, the ion-channel activity of the reconstituted P9-5-HT3A was effectively blocked by treatment with ondansetron, an antagonist of 5-HT3A.	Ondansetron	111-122	5-hydroxytryptamine receptor 3A	Homo sapiens	141-147
22924764-7	2013	Additionally, methylation levels of 6 CpGs (including cg08989585) in the HTR3A promoter region were analyzed in the replication sample.	cg08989585	54-64	5-hydroxytryptamine receptor 3A	Homo sapiens	73-78
22700043-0	2012	Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.	Clozapine	132-141	5-hydroxytryptamine receptor 3A	Homo sapiens	91-96
22700043-3	2012	Functionally important HTR3A gene single-nucleotide polymorphisms (SNPs) were reported to be associated with response to clozapine.	Clozapine	121-130	5-hydroxytryptamine receptor 3A	Homo sapiens	23-28
22700043-4	2012	OBJECTIVE: The aim of this study was to investigate how the association between HTR3A gene SNP and response to clozapine is influenced by various clinical predictors and by differing outcome definitions in patients with treatment-resistant schizophrenia (TRS).	Clozapine	111-120	5-hydroxytryptamine receptor 3A	Homo sapiens	80-85
22306960-0	2012	VUF10166, a novel compound with differing activities at 5-HT3A and 5-HT3AB receptors.	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	0-8	5-hydroxytryptamine receptor 3A	Homo sapiens	56-62
23115686-2	2012	Palonosetron, the newest 5-HT3 antagonist, has potent antiemetic property.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	25-30
22644261-1	2012	BACKGROUND: Previous reports suggested that selective serotonin reuptake inhibitors (SSRI) could decrease the activity of 5-hydroxytryptamine type 3 (5-HT3) antagonists against acute chemotherapy-induced nausea and vomiting (CINV), possibly through serotonin accumulation for 5-HT3 receptors.	Serotonin	122-141	5-hydroxytryptamine receptor 3A	Homo sapiens	150-155
22644261-1	2012	BACKGROUND: Previous reports suggested that selective serotonin reuptake inhibitors (SSRI) could decrease the activity of 5-hydroxytryptamine type 3 (5-HT3) antagonists against acute chemotherapy-induced nausea and vomiting (CINV), possibly through serotonin accumulation for 5-HT3 receptors.	Serotonin	122-141	5-hydroxytryptamine receptor 3A	Homo sapiens	276-281
22644261-1	2012	BACKGROUND: Previous reports suggested that selective serotonin reuptake inhibitors (SSRI) could decrease the activity of 5-hydroxytryptamine type 3 (5-HT3) antagonists against acute chemotherapy-induced nausea and vomiting (CINV), possibly through serotonin accumulation for 5-HT3 receptors.	cinv	225-229	5-hydroxytryptamine receptor 3A	Homo sapiens	150-155
22644261-1	2012	BACKGROUND: Previous reports suggested that selective serotonin reuptake inhibitors (SSRI) could decrease the activity of 5-hydroxytryptamine type 3 (5-HT3) antagonists against acute chemotherapy-induced nausea and vomiting (CINV), possibly through serotonin accumulation for 5-HT3 receptors.	cinv	225-229	5-hydroxytryptamine receptor 3A	Homo sapiens	276-281
22644261-1	2012	BACKGROUND: Previous reports suggested that selective serotonin reuptake inhibitors (SSRI) could decrease the activity of 5-hydroxytryptamine type 3 (5-HT3) antagonists against acute chemotherapy-induced nausea and vomiting (CINV), possibly through serotonin accumulation for 5-HT3 receptors.	Serotonin	54-63	5-hydroxytryptamine receptor 3A	Homo sapiens	150-155
22644261-1	2012	BACKGROUND: Previous reports suggested that selective serotonin reuptake inhibitors (SSRI) could decrease the activity of 5-hydroxytryptamine type 3 (5-HT3) antagonists against acute chemotherapy-induced nausea and vomiting (CINV), possibly through serotonin accumulation for 5-HT3 receptors.	Serotonin	54-63	5-hydroxytryptamine receptor 3A	Homo sapiens	276-281
22644261-7	2012	CONCLUSIONS: Our findings reinforce the hypothesis that SSRI decrease the antiemetic activity of the 5-HT3 serotonin antagonist ondansetron, resulting in higher rates of acute vomiting in cancer patients despite adequate antiemetic prophylaxis.	Serotonin	107-116	5-hydroxytryptamine receptor 3A	Homo sapiens	101-106
22644261-7	2012	CONCLUSIONS: Our findings reinforce the hypothesis that SSRI decrease the antiemetic activity of the 5-HT3 serotonin antagonist ondansetron, resulting in higher rates of acute vomiting in cancer patients despite adequate antiemetic prophylaxis.	Ondansetron	128-139	5-hydroxytryptamine receptor 3A	Homo sapiens	101-106
22589534-8	2012	The PU02 binding site in the 5-HT(3)R corresponds to allosteric sites in anionic Cys-loop receptors, which emphasizes the uniform nature of the molecular events underlying signaling through the receptors.	PU 02	4-8	5-hydroxytryptamine receptor 3A	Homo sapiens	29-37
22306960-2	2012	VUF10166 displaced [3H]granisetron binding to 5-HT3A receptors expressed in human embryonic kidney cells with high affinity (K(i) = 0.04 nM) but was less potent at 5-HT3AB receptors (K(i) = 22 nM).	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	0-8	5-hydroxytryptamine receptor 3A	Homo sapiens	46-52
22306960-2	2012	VUF10166 displaced [3H]granisetron binding to 5-HT3A receptors expressed in human embryonic kidney cells with high affinity (K(i) = 0.04 nM) but was less potent at 5-HT3AB receptors (K(i) = 22 nM).	Tritium	20-22	5-hydroxytryptamine receptor 3A	Homo sapiens	46-52
22306960-3	2012	Dissociation of [3H]granisetron in the presence of VUF10166 was best fit with a single time constant (t(1/2) = 53 min) at 5-HT3A receptors, but with two time constants (t(1/2) = 55 and 2.4 min) at 5-HT3AB receptors.	Tritium	17-19	5-hydroxytryptamine receptor 3A	Homo sapiens	122-128
22306960-3	2012	Dissociation of [3H]granisetron in the presence of VUF10166 was best fit with a single time constant (t(1/2) = 53 min) at 5-HT3A receptors, but with two time constants (t(1/2) = 55 and 2.4 min) at 5-HT3AB receptors.	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	51-59	5-hydroxytryptamine receptor 3A	Homo sapiens	122-128
22306960-4	2012	Electrophysiological studies in oocytes revealed that VUF10166 inhibited 5-HT-induced responses at 5-HT3A receptors at nanomolar concentrations, but inhibition and recovery were too slow to determine an IC50.	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	54-62	5-hydroxytryptamine receptor 3A	Homo sapiens	99-105
22306960-7	2012	At 5-HT3A receptors, VUF10166 at higher concentrations also behaved as a partial agonist (EC50 = 5.2 muM; R(max) = 0.24) but did not elicit significant responses at 5-HT3AB receptors at <=100 muM.	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	21-29	5-hydroxytryptamine receptor 3A	Homo sapiens	3-9
22306960-9	2012	The ability of VUF10166 to distinguish between 5-HT3A and 5-HT3AB receptors could help evaluate differences between these receptor types and has potential therapeutic value.	2-chloro-(4-methylpiperazine-1-yl)quinoxaline	15-23	5-hydroxytryptamine receptor 3A	Homo sapiens	47-53
23050164-2	2012	Ondansetron is a 5-hydroxytryptamine (5-HT(3), serotonin) receptor antagonist used as antiemetic prophylaxis preceding chemotherapy administration.	Ondansetron	0-11	5-hydroxytryptamine receptor 3A	Homo sapiens	38-66
23050164-2	2012	Ondansetron is a 5-hydroxytryptamine (5-HT(3), serotonin) receptor antagonist used as antiemetic prophylaxis preceding chemotherapy administration.	Serotonin	17-36	5-hydroxytryptamine receptor 3A	Homo sapiens	38-66
22694192-3	2012	The results of molecular dynamics simulations and computational alanine scanning mutagenesis studies applied here to the homomeric human 5-HT(3A)-R disclose an aromatic "hot" cluster in the centre of the interface formed by residues W178 (principal subunit), Y68, Y83, W85 and Y148 (complementary subunit).	Alanine	64-71	5-hydroxytryptamine receptor 3A	Homo sapiens	137-144
21420406-1	2011	BACKGROUND & AIMS: 5-Hydroxytryptamine (5-HT)3 receptor (5-HT3R) antagonists are effective in treating patients with irritable bowel syndrome (IBS) and have anxiolytic effects.	Adenosine Monophosphate	12-15	5-hydroxytryptamine receptor 3A	Homo sapiens	61-67
21948949-6	2011	Recently, we showed that channels functioned when the entire 5-HT3A M3-M4 loop was replaced by the heptapeptide M3-M4 loop sequence from GLIC, a bacterial Cys-loop neurotransmitter gated ion channel homologue from Gloebacter violaceus.	Cysteine	155-158	5-hydroxytryptamine receptor 3A	Homo sapiens	61-67
22044840-0	2011	Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses.	Irinotecan	16-26	5-hydroxytryptamine receptor 3A	Homo sapiens	46-52
21477640-3	2011	Here, we report that CBD and THC inhibited the function of human 5-HT(3A) receptors (h5-HT(3A)Rs) expressed in HEK 293 cells.	Cannabidiol	21-24	5-hydroxytryptamine receptor 3A	Homo sapiens	65-72
21477640-3	2011	Here, we report that CBD and THC inhibited the function of human 5-HT(3A) receptors (h5-HT(3A)Rs) expressed in HEK 293 cells.	Dronabinol	29-32	5-hydroxytryptamine receptor 3A	Homo sapiens	65-72
21420406-1	2011	BACKGROUND & AIMS: 5-Hydroxytryptamine (5-HT)3 receptor (5-HT3R) antagonists are effective in treating patients with irritable bowel syndrome (IBS) and have anxiolytic effects.	Serotonin	23-42	5-hydroxytryptamine receptor 3A	Homo sapiens	61-67
20168265-2	2010	In this study, we further investigated the role of the subunits A and B of the HTR3 receptor using 140 schizophrenia patients taking clozapine for 6 months.	Clozapine	133-142	5-hydroxytryptamine receptor 3A	Homo sapiens	79-83
20694841-3	2010	Prucalopride, the newest European Medicines Agency-approved 5-hydroxytryptamine receptor 4 (5-HT(4)) agonist, is effective in the treatment of chronic constipation with improved cardiovascular safety relative to older 5-HT(4) drugs; similarly, ramosetron, the 5-hydroxytryptamine receptor 3 (5-HT(3)) antagonist, appears efficacious in diarrhea-predominant IBS.	prucalopride	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	260-290
20694966-7	2010	CONCLUSIONS: These findings suggest that the HTR3A CC genotype may be associated with alterations in brain structures central to emotion processing, particularly when exposed to stress, and further highlight the potential role of the serotonin system in the pathophysiology of affective disorders.	Serotonin	234-243	5-hydroxytryptamine receptor 3A	Homo sapiens	45-50
21454663-7	2011	The P(Ca)/P(Cs) of 3.8 previously reported for the 5-HT(3)A(QDA) construct was reduced to 0.13 and 0.06 by the D127N and D127K mutations, respectively, with lesser, but clearly significant, effects caused by the D113N (1.04) and D113K (0.60) substitutions.	Cesium	12-14	5-hydroxytryptamine receptor 3A	Homo sapiens	51-59
21454663-9	2011	The data identify two key residues in the extracellular vestibule of the 5-HT(3)A receptor that markedly influence gamma, P(Ca)/P(Cs), and additionally the suppression of gamma by Ca(2+).	Cesium	130-132	5-hydroxytryptamine receptor 3A	Homo sapiens	73-81
21246737-2	2011	The design, synthesis, and functional characterisation of benzamide analogues at the 5-HT3A receptor yielded substantial information concerning the analogues as 5-HT3 receptor agonists.	benzamide	58-67	5-hydroxytryptamine receptor 3A	Homo sapiens	85-91
20724042-1	2010	Inhibition of the 5-hydroxytryptamine receptor (5-HT(3)R), a member of the Cys-loop superfamily of Ligand-Gated Ion Channels (LGICs), has been recognized to have important antiemetic effects.	Cysteine	75-78	5-hydroxytryptamine receptor 3A	Homo sapiens	48-56
20724042-2	2010	With respect to the many other drugs already in use, such as the first generation 5-HT(3)R antagonist granisetron, palonosetron, a second generation antagonist, clearly demonstrates superior inhibition potency towards the 5-HT(3)Rs.	Granisetron	102-113	5-hydroxytryptamine receptor 3A	Homo sapiens	82-90
20724042-2	2010	With respect to the many other drugs already in use, such as the first generation 5-HT(3)R antagonist granisetron, palonosetron, a second generation antagonist, clearly demonstrates superior inhibition potency towards the 5-HT(3)Rs.	Palonosetron	115-127	5-hydroxytryptamine receptor 3A	Homo sapiens	82-90
20724042-3	2010	Five different receptor monomers, the 5-HT(3)R A-E, have been identified although the A and B subunits are the only known to build functional receptors, the homopentameric 5-HT(3A)R and the heteropentameric 5-HT(3B-A)R (with BBABA subunit arrangement).	bbaba	225-230	5-hydroxytryptamine receptor 3A	Homo sapiens	38-46
20724042-6	2010	The results of docking studies of the natural agonist serotonin and the antagonists palonosetron and granisetron into the modelled homomeric and heteromeric 5-HT(3)R binding interfaces, provide a possible rationalization both of the higher potency of palonosetron with respect to other antagonists, and of its previously reported allosteric binding and positive cooperativity properties.	Serotonin	54-63	5-hydroxytryptamine receptor 3A	Homo sapiens	157-165
20724042-6	2010	The results of docking studies of the natural agonist serotonin and the antagonists palonosetron and granisetron into the modelled homomeric and heteromeric 5-HT(3)R binding interfaces, provide a possible rationalization both of the higher potency of palonosetron with respect to other antagonists, and of its previously reported allosteric binding and positive cooperativity properties.	Palonosetron	84-96	5-hydroxytryptamine receptor 3A	Homo sapiens	157-165
20724042-6	2010	The results of docking studies of the natural agonist serotonin and the antagonists palonosetron and granisetron into the modelled homomeric and heteromeric 5-HT(3)R binding interfaces, provide a possible rationalization both of the higher potency of palonosetron with respect to other antagonists, and of its previously reported allosteric binding and positive cooperativity properties.	Granisetron	101-112	5-hydroxytryptamine receptor 3A	Homo sapiens	157-165
20724042-6	2010	The results of docking studies of the natural agonist serotonin and the antagonists palonosetron and granisetron into the modelled homomeric and heteromeric 5-HT(3)R binding interfaces, provide a possible rationalization both of the higher potency of palonosetron with respect to other antagonists, and of its previously reported allosteric binding and positive cooperativity properties.	Palonosetron	251-263	5-hydroxytryptamine receptor 3A	Homo sapiens	157-165
20849671-2	2010	The best studied members of the Cys-loop family are nACh, 5-HT3, GABAA and glycine receptors.	Cysteine	32-35	5-hydroxytryptamine receptor 3A	Homo sapiens	58-63
20166948-3	2010	This review covers the authors" work performed during the past decade in the development of 5-HT(3)R ligands belonging to the class of arylpiperazine derivatives related to quipazine (quipazine-like arylpiperazines, QLAs) and represents the extension of the review previously published in Current Topics in Medicinal Chemistry in 2002.	arylpiperazine	135-149	5-hydroxytryptamine receptor 3A	Homo sapiens	92-100
20166948-3	2010	This review covers the authors" work performed during the past decade in the development of 5-HT(3)R ligands belonging to the class of arylpiperazine derivatives related to quipazine (quipazine-like arylpiperazines, QLAs) and represents the extension of the review previously published in Current Topics in Medicinal Chemistry in 2002.	Quipazine	173-182	5-hydroxytryptamine receptor 3A	Homo sapiens	92-100
20166948-3	2010	This review covers the authors" work performed during the past decade in the development of 5-HT(3)R ligands belonging to the class of arylpiperazine derivatives related to quipazine (quipazine-like arylpiperazines, QLAs) and represents the extension of the review previously published in Current Topics in Medicinal Chemistry in 2002.	Quipazine	184-193	5-hydroxytryptamine receptor 3A	Homo sapiens	92-100
20166948-3	2010	This review covers the authors" work performed during the past decade in the development of 5-HT(3)R ligands belonging to the class of arylpiperazine derivatives related to quipazine (quipazine-like arylpiperazines, QLAs) and represents the extension of the review previously published in Current Topics in Medicinal Chemistry in 2002.	arylpiperazines	199-214	5-hydroxytryptamine receptor 3A	Homo sapiens	92-100
19188483-3	2009	In contrast to the mouse receptor, coapplication of colchicine with 5-HT (<1 microM) strongly enhanced 5-HT-evoked currents in oocytes expressing human 5-HT(3A)Rs.	Colchicine	52-62	5-hydroxytryptamine receptor 3A	Homo sapiens	155-162
19513770-8	2009	The positive wave is assigned to 5-HT3A receptors in the free membrane that drive a potassium outward current through the adherent membrane.	Potassium	84-93	5-hydroxytryptamine receptor 3A	Homo sapiens	33-39
19513770-9	2009	The negative wave is attributed to 5-HT3A receptors in the adherent membrane that are activated with a delay due to serotonin diffusion.	Serotonin	116-125	5-hydroxytryptamine receptor 3A	Homo sapiens	35-41
20124604-0	2009	Expression changes of serotonin receptor gene subtype 5HT3a in peripheral blood mononuclear cells from schizophrenic patients treated with haloperidol and Olanzapin.	Haloperidol	139-150	5-hydroxytryptamine receptor 3A	Homo sapiens	54-59
20124604-0	2009	Expression changes of serotonin receptor gene subtype 5HT3a in peripheral blood mononuclear cells from schizophrenic patients treated with haloperidol and Olanzapin.	Olanzapine	155-164	5-hydroxytryptamine receptor 3A	Homo sapiens	54-59
19184136-8	2009	These data suggest that variation within genes on the serotonin pathway, particularly HTR3A, may have modest effects on autism risk.	Serotonin	54-63	5-hydroxytryptamine receptor 3A	Homo sapiens	86-91
19232535-11	2009	These results suggest that 5-HT(3)R activation, coupled with increased intracellular calcium, can transiently alter postsynaptic excitability in IC neurons.	Calcium	85-92	5-hydroxytryptamine receptor 3A	Homo sapiens	27-35